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ITP-001: THE IMMUNOHISTOCHEMICAL STUDIES ON THE TYPE 
AB THYMOMA
Yukari Miki, Atsushi Hayashi, Kiyoshi Takahashi  
Department Of Medical Technology, Graduate School Of Health Sciences, Okayama 
University, Okayama/JAPAN
Background: The type A thymoma is composed solely of spindle-shaped neoplastic 
epithelial cells (NEC), while the type B (B1-B3) thyomas are composed of polygonal-shaped 
NEC and varied amounts of intermingled non-neoplastic immature T-lymphocytes 
(thymocytes). The type AB thymoma has generally been regarded as a mere mixture of type 
A and type B thymomas. Little is, however, known about the nature of type AB thymoma. 
In this study, we attempted to disclose the nature of type AB thymoma. We examined NEC 
in type AB thymoma immunohistochemically, and compared them with those in other 
types of thymoma, including type A, type B1, and metaplastic thymomas. We also focused 
on the distribution of non-neplastic tumor accompanied cells, such as thymocytes and 
thymic cortical dendritic macrophages (TCDM), which are newly identified thymic cortex-
specific macrophages of the human thymus. Methods: Formalin-fixed, paraffin-embedded 
tissues of type A thymoma (10 cases), metaplastic thymoma (1 case), type AB thymoma 
(19 cases), and type B1 thymoma (15 cases) were examined immunohistochemically 
using monoclonal antibodies against pancytokeratin (CK-AE1/AE3), claudin-1, 
vimentin, epithelial membrane antigen (EMA), CD99, fascin, and HLA-DR. Results: 
In type A thymoma, NEC were composed solely of short spindle cell strongly positive 
for CK-AE1/AE3 and claudin-1, and negative for vimentin and HLA-DR. Metaplastic 
thymoma exhibited biphasic architecture of epithelial islands of short spindle NEC and 
anastomosing bundles of fibroblast-like NEC. The short spindle NEC were phenotypically 
almost identical to NEC in type A thymoma, while fibroblast-like NEC were metaplastic 
fibroblast-like cells negative for CK-AE1/AE3 and claudin-1 and positive for vimentin and 
EMA. Type B1 thymoma were composed of NEC closely similar to normal cortical thymic 
epithelial cells (cTEC) and numerous intermingled CD99+ thymocytes and conspicuous 
fascin+ TCDM. These findings indicated that the architecture of type B1 thymoma is 
closely similar to that of the normal thymic cortex. Type AB thymoma was a variable 
mixture of type A-like and type B-like areas. The type B-like areas were composed of 
peculiar NEC extending numerous complexed cytoplastmic projections and numerous 
CD99+ thymocytes and a few inconspicuous poorly developed TCDM. In 5 cases of type 
AB thymoma, which we designated as “conventional subtype”, type A-like components 
were composed of short spindle NEC immunophenotypically almost identical with NEC 
in type A thymomas. In contrast, in 14 cases, which were designated as “metaplastic 
subtype”, type A-like areas were composed solely of elongated fibroblast-like NEC, which 
were immunophenotypically almost identical with the fibroblast-like NEC in metaplastic 
thymoma. Conclusion: Type AB thymoma is not mere mixture of type A and type B1 
thymomas. In all cases of type AB thymoma, type B-like areas were different from type 
B1 thymoma. Type B-like components of type AB thymoma may represent immature or 
undeveloped thymic cortex. Moreover, the present analysis on type A-like areas indicates 
that there are two distinct subtypes in type AB thymoma, “metaplastic subtype” and 
“conventional subtype”. “Metaplastic subtype” is the major subtype of type AB thymoma, 
while “conventional subtype” is the miner one.
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ITP-002: THE IMMUNOHISTOCHEMICAL DISTINCTION OF THY-
MIC CARCINOMA FROM LUNG SQUAMOUS CELL CARCINOMA 
AND TYPE B3 THYMOMA
Atsushi Hayashi1, Yukari Miki2, Kiyoshi Takahashi3  
1Pathological Department, Okayama Red Cross Hospital, Okayama/JAPAN, 
2Department Of Medical Technology, Kagawa Prefectural University Of Health Sciences, 
Kagawa/JAPAN, 3Department Of Medical Technology, Graduate School Of Health 
Sciences, Okayama University, Okayama/JAPAN
Background: Thymic carcinomas are rare epithelial neoplasms of anterior mediastinum 
with highly malignant nature and thought to be derived from epithelial cells of thymic 
origin. It is very important to differentiate thymic carcinoma from type B3 thymoma 
and lung SCC, because the biological behavior of and the therapy for thymic carcinoma 
are usually very different from those of these tumors. In this study, we attempted to find 
useful immunohistochemical markers to distinguish thymic carcinomas from type B3 
thymomas and lung SCC. Methods: Thymic carcinoma ,12 cases of type B3 thymoma, 
and 12 cases of lung SCC were retrieved from pathology files of the Okayama Red 
Cross Hospital and Okayama University Hospital. Commercially available monoclonal 
antibodies against cytokeratin AE1/AE3 (pan-CK), c-kit, MIB-1, synaptophisin, claudin-1 
(CLDN-1), fascin, HLA-DR, CD68, CD99, CD205, p53, CLDN-1, Glut-1, and CD5 were 
used. We also prepared rabbit polyclonal antibody to human thymic proteasome subunit 
β5t, which is specific for cortical thymic epithelial cells (cTEC). Results: In all cases of 
thymic carcinomas examined, tumors were composed of solid sheets of polygonal pan-
CK+ neoplastic epithelial cells (NEC) without squamous or glandular differentiation and 
abundant hyalinized fibrous stroma. In these cases, cellular atypia of NEC was manifest 
and mitotic figures and necrotic foci of NEC were frequently observed. In 11 out of 12 
cases of thymic carcinoma, NEC were positive for c-kit, and the immunoreactions for c-kit 
were detected intensely at cell-membrane and in cytoplasm of NEC. In contrast, a weak 
cytoplasmic immunostaining for c-kit was detected in only 2 out of 12 cases of lung SCC. 
The membranous and cytoplasmic immunostaining for c-kit were detected in NEC of only 
2 out of 12 cases of type B3 thymoma. CLDN-1 was detected at cell-membrane of NEC in 
all cases of thymic carcinomas and Lung SCC, while it was detected in only 2 cases of type 
B3 thymoma. Average of MIB-1 index of thymic carcinomas (26.0) were not significantly 
different from that of Lung SCC (35.7), but it was significantly higher than that of B3 
thymoma (8.8) (p<0.05). CD5 was detected in 7 of 12 cases of thymic carcinoma, while 
this antigen was detected in only 1 out of 12 cases of type B3 thymoma and none in 12 
cases of lung SCC. Thymic proteasome β5t was detected in all cases of type B3 thymoma, 
but was not detected in any case of thymic carcinoma or lung SCC. Nonneoplastic thymic 
resident cells, such as thymocytes and thymic cortical dendritic macrophages (TCDM), 
which are newly identified thymic cortex-specific macrophages, were not detected in 
any cases of thymic carcinoma or SCC, while they were detected in type B3 thymomas 
in varied numbers. Conclusion: The present study indicates that c-kit,β5t, CLDN-1, and 
MIB-1-index are useful to distinguish thymic carcinoma from type B3 thymoma, and that 
c-kit and CD5 are useful to distinguish thymic carcinoma from lung SCC. It seems likely 
that using the combination of these immunohistochemical markers makes it possible to 
distinguish thymic carcinoma from type B3 thymoma or lung SCC almost completely.
Keywords: type B3 thymoma, lung SCC, thymic carcinoma
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ITP-003: SPINDLE CELL VARIANTS OF TYPE B3 THYMOMA HAS 
THE TENDENTIOUS BEHAVIOR OF LUNG METASTASIS.
Gang Chen  
Pathology, Shanghai Pulmonary Hospital, School Of Medicine, Tongji University, 
Shanghai/CHINA
Background: Spindle cell variants of type B3 thymoma is a very rare thymoma that shows 
the characteristics of spindle tumour cells in morphorlogy,which is easily misdiagnosed 
as type A thymoma and makes troubles in this decade.In recent ITMIG Consensus 
Slide Workshop at Heidelberg, this tumour is tentatively delineated as “Atypical type 
A thymoma”. Methods: Ten cases of spindle cell variants of type B3 thymomas were 
diagnosed after the differential diagnosis with immunohistochemistry and morphology 
consultation of three famous pathologists. Results: Clinically,9 male and 3 female,age from 
44 to 86 years old and average is 56.Imaging and grossly,the main mass is about 3 to 8 cm 
in diameter and 4 cases with lung metastasis.Histologically,the tumour predominantly 
composed of spindle tumour cells with rare lymphocytes among them.Tumour cells 
exhibit nuclear hyperchromasia,pleomorphism,mitotic activity and /or necrosis.Differently 
to the type A thymoma,this tumour shows mimic organic growth pattern of palisading 
cells around perivascular spaces with tiny T lymphocytes infiltration in some area and p53 
positive is often seen. Follow-up,most of them are not sensitive to the chemotherapy but 
alive with tumour progress slowly. Conclusion: Spindle cell variants of type B3 thymoma 
is differently to type A thymoma in biological behavior and typical B3 in morphology.
Jumping metastasis to the lung is often seen in this rare tumour.
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ITP-004: CLINICOPATHOLOGICAL ANALYSIS OF SMALL-SIZED 
THYMOMA WITH PODOPLANIN AND KI 67 EXPRESSION 
ANALYSIS
Keisuke Yokota1, Motoki Yano2, Satoru Moriyama2, Yu Hikosaka2, Katsuhiro Okuda2, 
Masayuki Shitara2, Meinoshin Okumura3, Kohei Yokoi4, Yoshitaka Fujii2  
1Chest Surgery, Toyota Memorial Hospital, Toyota Aichi/JAPAN, 2Oncology, 
Immunology And Surgry, Nagoya City University Graduate School Of Medical Sciences/
JAPAN, 3General Thoracic Surgery, Osaka University Graduate School Of Medicine/
JAPAN, 4Thoracic Surgery, Nagoya University Graduate School Of Medicine/JAPAN
Background: Thymoma is the most common tumor of the anterior mediastinum 
for which surgical resection is currently the primqry form of treatment. An increase 
in the incidence of a small-sized (≦3cm) thymoma (SST) has recently been noted. 
Clinicopathological factors and prognosis of STT have not been reported previously. 
Methods: In this study, the clinicopathological data of 21 SST patients were reviewed and 
podoplanin and Ki67 immunohistochemistry were assessed to determine the biological 
behavior of SSTs.  Results: Pathological diagnosis of SSTs revealed the following: type 
A (n=1), AB (n=8), B1 (n=5), B2 (n=6), and B3 (n=1). The Masaoka-Koga stages of 21 
thymoma patients were I (n=16), II (n=3), III (n=1), and IVb (n=1). In the case with stage 
IVb thymoma, phrenic nerve and mediastinal pleura invasion and anterior mediastinal 
lymph node metastasis were observed. Ki67 labeling index of this stage IVb was 3.2. 
This case was also positive for podoplanin and was one of the only 2 that were positive 
for podoplanin. This patient succumbed to thymoma.  Conclusion: Advanced stage 
thymomas are possibly included in SSTs although the majority of SSTs are classified 
into early stages of disease. Findings of this study suggest that podoplanin analyzed by 
immunohistochemistry may be useful to determine the malignant behavior of SSTs.
Keywords: thymoma, small-sized, Ki67, podoplanin
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ITP-005: MICROARRAY ANALYSIS FOR CD CLASSIFICATION OF 
THYMIC EPITHELIAL CELL SUBPOPULATIONS
Chikako Takai1, Yaushi Nakagawa2, Kazuya Kondo1, Yousuke Takahama3  
1Department Of Oncological Medical Services, Institute Of Health Biosciences, The 
University Of Tokushima, Tokushima/JAPAN, 2Experimental Immunology, Institute For 
Genome Research, University Of Tokushima, Tokushima/JAPAN, 3Institute For Genome 
Research, University Of Tokushima, Tokushima/JAPAN
Background: Thymic microenvironments, where T cells are generated and selected, 
are composed of various discrete subsets of thymic stromal cells (TSCs), including 
thymic cortical epithelial cells (cTECs), thymic medullary epithelial cells (mTECs), 
and fibroblasts. Currently, TSC subsets are often classified using functionally unknown 
markers, for example Ly-51, UEA-1, and MTS-15, which cannot be readily applied to the 
classification of human TSCs. Methods: Towards the improvement of TSC classification 
technology, microarray analysis for purified Ly51+UEA1- cTECs and Ly51-UEA1+ mTECs 
of C57BL/6 mice was carried out using Affimetrix gene chips. Focusing on CD genes, 
quantitative RT-PCR analysis was also performed. Results: Those results revealed that 
33 CD genes including CD80 and CD265 were expressed in mTECs more than twice as 
strongly as cTECs, whereas 18 CD genes including CD205 and CD274 were expressed 
in cTECs more than twice as strongly as mTECs. Conclusion: We found that some CD 
molecules are useful for analysis of human thymic epithelial cells. Examination of these 
CDs for classification of TEC subsets in mouse and human is currently in progress.
Keywords: thymic epithelial cells, thymoma
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ITP-006: A GERMLINE EGFR GENE MICROSATELLITE CASSRI 
POLYMORPHISM WITH SHORT ALLELES AND POLYSOMY /
INCREASED GENE COPY NUMBER DETECTED BY EGFR GENE/
CHROMOSOME 7 – FISH IS CONSISTENTLY ASSOCIATED TO  
SUBTYPE B THYMOMA
Mirella Marino1, Stefano Sioletic1, Francesco Facciolo2, Enzo Gallo1, Libero Lauriola3, 
Amelia Evoli4, Pierluigi Granone5, Giovannella Palmieri6, Mariangela Novello3, Anna Di 
Benedetto1, Flavia Novelli7, Edordo Pescarmona1, Salvatore Conti1  
1Pathology, Italian National Cancer Institute “Regina Elena”, Rome/ITALY, 2Thoracic 
Surgery, Italian National Cancer Institute “Regina Elena”, Rome/ITALY, 3Pathology, 
Catholic University, Rome/ITALY, 4Neurosciences, Catholic University, Rome/ITALY, 
5Thoracic Surgery, Catholic University, Rome/ITALY, 6Endocrinology And Molecular 
And Clinical Oncology, Federico Ii University, Naples/ITALY, 7ut Radiation Biology And 
Biomedicine, Enea C.R. Casaccia, Rome/ITALY
Background: In the management of Thymic Epithelial Tumors (TET), relevant 
prognostic factors include WHO histology and Masaoka stage.Additional biological 
factors should be identified at the diagnosis, as data support the view that, among TET, 
the organotypic Thymomas show uncertain malignant potential. Our multicenter 
multidisciplinary network enables us to follow long term survivor thymoma patients 
. We analyzed an egfr gene germline polymorphism related to the CASSRI locus 
microsatellite: in a series of 43 cases the prevalent genotype included homozygous for 16 
CA repeats and the second included heterozygous with16 and 20 CA repeats , while the 
presence of long alleles ( ≥18 CA repeats ) was rare. Moreover, 4 out of 29 heterozygous 
informative cases showed Loss of Heterozygosity (LOH), an Allelic Imbalance (AI), at 
CASSRI locus of the EGFR microsatellite, 3 out of 4 with loss of the longer allele with 
respect to the shorter allele, as detected by tumor / normal tissue comparison. Methods: 
Formalin-fixed, paraffin embedded (FFPE) tumor tissue was evaluated by EGFR/CEN-7 
FISH Probe mix (Dako). Microsatellite analysis for CASSRI locus was performed on 
genomic DNA by PCR amplification and Fluorescent capillary electrophoresis on a 
3130 Genetic Analyzer, APPLIED BIOSYSTEMS®. DNA from tumors, non neoplastic 
thymus and normal tissue was used for LOH analysis. Results: By integrating LOH 
and egfr-FISH derived data and by Spearman χ2 test statistical analysis we show here 
that cases harboring the shorter CASSRI egfr alleles (average of alleles length for (CA)
n sum ) were significantly associated to the WHO B subtype (B2 and B3 and mixed B2/
B3 forms) of thymoma. Three out of the 4 AI positive cases were significantly associated 
with the B subtype according to the 2004 WHO classification and 1 was associated 
with the AB subtype. By statistical analysis, all CASSRI-AI positive cases were found 
to be significantly associated to stage III disease. Eight out of 32 cases analysed by 
chromosome 7 egfr-FISH analysis showed chromosome 7 polysomy/increased gene copy 
number. The 4 cases in Stage II were “polysomic” with 3 “chromosome 7”/cell, whereas 
4 cases in Stage III showed >3 “chromosomes 7”/cell. A statistically significant positive 
correlation was found between FISH-determined “ polysomy” and the 4 CASSRI-AI 
positive cases (p<0.0001) when we considered the number of chromosome 7 copies/
increased copy number per cell. Among the 4 “polysomic” cases in Stage II, one was 
a type A thymoma which gave subsequently cerebral metastases, one was in the AB 
subtype, one had a B1 and one had a B3 subtype. Among the Stage III “polysomic” 
cases, 2 relapsed (1 patient died of infectious complications after 20 years, the second 
case relapsed 3 times and patient is living since 10 years after the diagnosis). Relapsed 
tumours/metastases proved to be stable with respect to tumor subtyping and to genetic 
data. Conclusion: Egfr CASSRI microsatellite analysis and LOH data together with egfr/
CEN7 derived FISH data support the relevance and subtype relationship of egfr gene in 
the diagnostic/ prognostic workup of thymoma cases.
Keyword: egfr /FISH/microsatellite/LOH
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ITP-007: A 19-GENE PROGNOSTIC GEP SIGNATURE TO DETER-
MINE METASTATIC RISK ASSOCIATED WITH THYMOMAS
Yesim Gokmen-Polar1, Robert W. Cook1, Chirayu P. Goswami2, Kristen M. Oelschlager1, 
Derek Maetzold1, John Stone1, Jeff Wilkinson1, Ioan T. Vladislav3, Kristen L. Shirar2, 
Kenneth A. Kesler1, Patrick J. Loehrer1, Sunil S. Badve3  
1Medicine, Indiana University School Of Medicine, Indianapolis/IN/UNITED STATES 
OF AMERICA, 2Medicine, Indiana University School Of Medicine, Indianapolis/
UNITED STATES OF AMERICA, 3Pathology And Laboratory Medicine, Indiana 
University School Of Medicine, Indianapolis/IN/UNITED STATES OF AMERICA
Background: Adjuvant therapy decisions for patients with thymomas are made on 
tumor stage as determined by histologic classification and extent of resection. These 
tools have low limited prognostic accuracy. Improving the accuracy of predicting 
likelihood of metastasis (or recurrence) through a molecular prognostic tool should 
enable better management of patients. Methods: Reverse-transcriptase-polymerase-
chain-reaction (RT-PCR) assay for 23 genes (19 test and 4 reference genes) was performed 
on multi-institutional archival paraffin-embedded primary thymomas (n=36). The gene 
expression levels were used to compute gene expression profile (GEP) signature and 
classify tumors into low or high risk. The GEP was validated in a multi-institutional 
independent test set (n=75) of patients. Results: We developed and validated a 19 gene 
prognostic GEP signature for predicting metastatic behavior in thymomas. Using radial 
basis machine (RBM) modeling in the training set, both 5-year and 10-year MFS rates 
were 85% and 22% for predicted low risk and high risk of metastasis (P<0.0005, Log-
Rank), respectively. For the validation set, 5- year MFS rates were 93% and 35% for 
predicted low and high risk patients (P<0.0018 Log-Rank), respectively. The 5- year MFS 
rates for Masaoka stage in the validation set were 53% and 41% for Stage I/II and Stage 
III/IV(P<0.0433 Log-Rank), respectively. In a multivariate Cox model, the GEP was the 
only independent predictor of metastasis free survival compared to age at diagnosis 
and stage (p=0.048). Conclusion: Using archival tissues, we identified and validated a 
19-gene signature that predicts likelihood of metastases of thymomas more accurately 
than traditional staging. The signature provides insights for both improved patient 
stratification and targeted therapy.
Keywords: thymoma, prognostic gene signature, metastatic risk
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ITP-008: DURABLE RESPONSE WITH ORAL PPARγ AGONIST 
EFATUTAZONE (CS-7017) IN A PRETREATED PATIENT WITH 
ADVANCED THYMIC CARCINOMA
Haruyasu Murakami1, Akira Ono1, Takehito Shukuya1, Hiroaki Akamatsu1, Tetsuhiko 
Taira1, Hirotsugu Kenmotsu1, Tateaki Naito1, Toshiaki Takahashi1, Masahiro Endo2, 
Nobuyuki Yamamoto1  
1Division Of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka/JAPAN, 2Division 
Of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka/JAPAN
Background: Advanced thymic carcinoma is a rare disease, and no standard 
chemotherapy has yet been established. Glucocorticoid receptor (GR) expression is 
associated with better prognosis for thymic carcinoma. Efatutazone (CS-7017), a novel 
third-generation thiazolidinedione, is a highly selective agonist of the peroxisome 
proliferator-activated receptor-γ (PPARγ). PPARγ is one of nuclear hormone 
receptor, which is a key regulator of cellular metabolism and a therapeutic target in 
carcinogenesis. PPARγ agonist efatutazone is also partial agonist for GR, and has 
demonstrated anti-tumor activity in several cancer cell lines and xenograft models. 
Methods: We describe a case of advanced thymic carcinoma that responded to third-
line chemotherapy with oral PPARγ agonist efatutazone. Efatutazone was provided 
by Daiichi Sankyo Pharmaceutical Co., Ltd (Tokyo, Japan). Results: A 63-year-old 
man was diagnosed to have advanced thymic carcinoma (type C according to the 
WHO classification of thymic neoplasms) with pulmonary metastasis and pleural 
dissemination. The patient was initially treated with chemotherapy with 4 cycles of 
carboplatin and paclitaxel; tumor assessment showed a stable disease but disease 
progression after 4 cycles. The patient was treated with a second-line therapy with 
ganitumab (AMG479), a novel human monoclonal antibody against the insulin-like 
growth factor receptor type I; tumor assessment showed a stable disease but disease 
progression after 48 weeks. On January 2011, a computed tomography (CT) showed 
clear pleural dissemination progression, and the patient had a complaint of worsening 
chest pain. The patient enrolled in a phase 1 study of oral PPARγ agonist efatutazone and 
started treatment as a third-line chemotherapy. Efatutazone was administered at doses of 
0.50 mg twice daily for 21-day cycles. Treatment was continued in the absence of disease 
progression or unacceptable toxicity. Treatment was well tolerated, and an improvement 
in symptom control was registered. Tumor assessment showed a partial response, and a 
response lasted for 1 year and more. The patient had received continuous treatment with 
efatutazone for 70 weeks until disease progression.  Conclusion: Oral PPARγ agonist 
efatutazone has showed durable response in a pretreated patient with advanced thymic 
carcinoma. Further evaluation of efatutazone for thymic carcinoma is warranted.
Keywords: Efatutazone, chemotherapy, thymic carcinoma, PPARγ
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ITP-009: EVEROLIMUS PLUS LONG-ACTING SOMATOSTATIN 
ANALOGS IN THYMIC EPITHELIAL MALIGNANCIES
Giovannella Palmieri1, Carlo Buonerba1, Piera Federico2, Lucia Nappi1, Luigi Formisano1, 
Giuseppe Di Lorenzo1, Mirella Marino3, Sabino De Placido1, Vincenzo Damiano1  
1Endocrinologia Ed Oncologia Molecolare E Clinica, Università Degli Studi Di Napoli 
“Federico Ii” - Centro Riferimento Tumori Rari (Crtr), Napoli/ITALY, 2Endocrinologia 
Ed Oncologia Molecolare E Clinica, Università Degli Studi Di Napoli “Federico Ii”- 
Centro Riferimento Tumori Rari (Crtr), Napoli/ITALY, 3Pathology, Italian National 
Cancer Institute “Regina Elena”, Rome/ITALY
Background: Although thymic epithelial tumors (TETs) are rare in the general population, 
they represent the most frequently diagnosed primary malignant tumor of the anterior 
mediastinum. Unlike localized disease, metastatic TETs are invariably fatal. While several 
chemotherapy agents have proven to be effective in TETs, somatostatin analogs are the 
only targeted agents with an established role in this disease. Methods: Everolimus is an 
mTOR inhibitor with multiple application in solid tumors, such as kidney cancer and 
neuroendocrine tumors. Records of patients treated for advanced TETs at our Institution 
in the last five years were retrospectively reviewed and data regarding those treated with 
everolimus were extracted. Results: Two female patients, respectively affected by a B2 
and B3 TET, were treated with everolimus (10 mg daily) at our Institution after they had 
received several lines of chemotherapy. They both presented a large mediastinal mass 
with dyspnea and pain. A marked clinical benefit and a radiological disease control were 
documented with oral everolimus in both patients, with an excellent toxicity profile (G1 
diahrrea, G2 hyperglycemia, G2 fatigue). After about 18 months of treatment, both patients 
are still on everolimus, with no evidence of progressive disease. Conclusion: Given the 
paucity of therapeutic options for this disease and the encouraging results obtained in 
this report, our work-group is going to lead a multi-institutional phase II trial to evaluate 
safety and efficacy of everolimus in thymic epithelial malignancies. Approximately 40 
patients will be enrolled in this trial, which will focus on efficacy predictive factors (such as 
expression and phosphorylation of mTOR), besides everolimus safety and effectiveness.
Keywords: TET, mTOR, somatostatin analogs
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ITP-010: A PROPOSAL OF A NEW METHOD FOR MEDIASTINAL 
COMPARTMENT CLASSIFICATION OF TRANSVERSE PLANE IM-
AGE BASED ON THE JAPANESE ASSOCIATION FOR RESEARCH 
ON THE THYMUS (JART) GENERAL RULES FOR STUDY OF MEDI-
ASTINAL TUMORS
Kiminori Fujimoto1, Masaki Hara2, Noriyuki Tomiyama3, Masahiko Kusumoto4, 
Fumikazu Sakai5, Yoshitaka Fujii6  
1Department Of Radiology And Center For Diagnostic Imaging, Kurume University 
School Of Medicine, Kurume/JAPAN, 2Department Of Radiology, Nagoya City University 
Graduate School Of Medical Sciences, Nagoya/JAPAN, 3Radiology, Osaka University 
Graduate School Of Medicine, Suita/JAPAN, 4Department Of Radiology, National Cancer 
Center Hospital/JAPAN, 5Department Of Diagnostic Radiology, Saitama International 
Medical Center, Saitama Medical University, Hidaka/JAPAN, 6Oncology, Immunology And 
Surgery, Nagoya City University Graduate School Of Medical Sciences, Nagoya/JAPAN
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Background: There were several classification methods for mediastinal compartment 
model: (a) Traditional method; (b) Fraser method; (c) Zylak method; (d) Felson method; 
and (e) Heitzman method. What is confusing is the fact that different authors use different 
terms for the same thing. Among these methods, the classification of the mediastinum 
into 3 compartments by Felson is strictly a radiological one. The main advantage of it is 
that it is practical and it works. However, because the Felson’s classification used lateral 
radiograph, the anterior compartment includes some masses both in anterior and middle 
mediastinum and the middle compartment includes some masses both in the middle 
and posterior mediastinum. These are not distinguishable on the radiograph. Therefore, 
the classification of mediastinum compartment based on the transverse plane image 
obtained by x-ray computed tomography (CT), which is made into the standard method, 
is needed. The diagnostic radiologists of the Japanese Association for Research on the 
Thymus (JART) proposed a new method for mediastinal compartment of transverse 
plane image. The purpose of this exhibit is to demonstrate this classification method 
for clinically practical use. Methods: The aim of this classification for mediastinum 
compartment was to contribute to clinically practical and more exact presence diagnosis. 
In a setup of this classification, we evaluated CT images of large number of mediastinal 
neoplasms. First, we present to view and understand the new classification method for 
mediastinal compartment of transverse plane image. Next, we subdivided 455 cases 
of mediastinal masses into each compartment region by using the new mediastinal 
compartment classification method. Finally, we demonstrate that to subdivide each mass 
into each existing compartment by using this classification of mediastinal compartment 
is user-friendly for classifying and useful for differential diagnoses. Results: We proposed 
the four compartments of mediastinum in transaxial CT images as follows: superior 
portion of mediastinum; anterior mediastinum (prevascular zone); middle mediastinum 
(peritracheoesophageal zone); and posterior mediastinum (paravertebral zone). We 
demonstrate illustrations and CT images for recognizing these compartments. All of 
455 mediastinal masses were subdivided into each existing mediastinal compartment 
completely. Majority of intrathoracic goiter and quarter of neurogenic tumors existed 
in the superior portion of mediastinum; all of thymic masses existed in the anterior 
mediastinum; neuroenteric cystic masses existed in the middle mediastinum; and three-
quarters of neurogenic tumors existed in the posterior mediastinum. Conclusion: This 
is the presentation of a definition for the classification of mediastinal compartments for 
differential diagnosis based on the transverse plane image. The anatomic mediastinal 
compartment proposed in this presentation is a reasonable classification and user-friendly 
for practical and clinical use of the transverse plane image.
Keywords: Mediastinal masses, Mediastinal compartment, Differential diagnosis, 
Computed tomography
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ITP-011: CT STAGING AND PREOPERATIVE ASSESSMENT OF 
RESECTABILITY FOR THYMIC EPITHELIAL TUMORS
Teng Mao1, Wenhu Chen2, Wentao Fang3  
1Thoracic Surgery, Shanghai Chest Hospital, Shanghai/CHINA, 2Department Of 
Thoracic Surgery, Shanghai Chest Hospital,Shanghai Jiaotong University, Shanghai/
CHINA, 3Department Of Thoracic Surgery, Shanghai Chest Hospital, Shanghai/CHINA
Background: Tumor stage and completeness of resection are the most important 
prognostic factors for thymic epithelial tumor (TET). Computed tomography (CT) is 
the most often used imaging tool for preoperative assessment of TET. There have been 
only a few published reports describing the CT characteristics of TET with reference 
to Masaoka staging. And there has been no previous study examining the relationship 
between CT appearance and resectability of TET. The aim of this study was to determine 
the CT features potentially helpful for accurate staging and predicting resectability of 
TET. Methods: One-hundred and thirty-eight consecutive TET patients undergone 
surgical resection during April 2010 to November 2011were prospectively entered into 
a database. All patients were staged according to the Masaoka-Koga staging system. 
The relationship between CT features with tumor staging and complete resection was 
reviewed after surgery. Results: Surgico-pathological staging was stage I in 63, stage II 
in 32, stage III in 32, and stage IV in 11 patients. Shape, contour, enhancement, with or 
without invasion of the adjacent structures (mediastinal fat, mediastinal pleura, lung, 
pericardium, mediastinal vessels, phrenic nerve),and presence of pleural, pericardial 
dissemination or intrapulmonary metastasis were correlated with Masaoka-Koga 
staging (p<0.05). On the other hand, tumor size, location, homogeneity or presence of 
calcification were not related to staging (p>0.05). The sensitivity (87.3%vs47.4, p<0.05) for 
CT judgment of invasion into adjacent structures (mediastinal fat, mediastinal pleura, 
lung, pericardium, mediastinal vessels, phrenic nerve) was higher than CT judgment of 
pleural or pericardium dissemination, pulmonary metastasis and mediastinal lymph node 
metastasis. The specificity(91.4%vs53.7, p<0.05) for CT diagnosis of tumor invasion into 
lung, pericardium, mediastinum vessels, phrenic nerve was higher than CT diagnosis of 
tumor invasion of mediastinal fat or mediastinal pleura. The specificity for CT judgment of 
pleural or pericardial dissemination and pulmonary metastasis was 100%. Preoperative CT 
staging was consistent with postoperative surgico-pathological staging (Kappa=0.525). For 
stage I and IV tumors, sensitivity(45.9%) was relatively low and specificity( 99.5%)high. For 
stage II and III tumors, sensitivity(89.1%) was relatively high and specificity(78.3%) low. 
Tumor location or presence of calcification were not correlated with complete resection of 
tumor (p > 0.05). Tumor X-diameter, shape, contour, homogeneity, enhancement, invasion 
of adjacent structures were related to complete resection under univariate analysis(p<0.05). 
However, upon multivariate logistic regression, only absence of mediastinal vessel invasion 
was predictive of complete resection (p<0.05). Conclusion: Clinical staging of TET could 
be accurately evaluated via CT features including tumor shape, contour, enhancement, 
with or without invasion of adjacent structures, and presence of pleural, pericardial 
dissemination or intrapulmonary metastasis. Absence of mediastinal vessel invasion on 
CT was the only predictive feature for predicting complete resection of TET.
Keywords: complete resection, thymic tumor, computer tomography (CT), tumor stage
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ITP-012: COMBINATION CHEMOTHERAPY WITH DOXORUBI-
CIN, VINCRISTINE, CYCLOPHOSPHAMIDE, AND PLATINUM 
COMPOUNDS FOR ADVANCED THYMIC CARCINOMA
Tomonobu Koizumi1, T Agatsuma2, Kazunari Tateishi3, Toshiro Fukushima3, K 
Sonehara2, M Ikeda2, F Kinoda2, T Ichiyama2, M Hama3, M Horiuchi3, K Ikegami3, 
Y Tokoro3, A Ushiki3, T Yokoyama3, T Kobayashi3, M Yasuo3, K Urushihata3, H 
Yamamoto3, M Hanaoka3, K Kubo3  
1Comprehensive Cancer Center, Shinshu University School Of Medicine, Matsumoto/
JAPAN, 2Shinshu University School Of Medicine/JAPAN, 3, Shinshu University School 
Of Medicine/JAPAN
Background: The optimal chemotherapy for unresectable advanced thymic carcinoma 
has not yet been established because of its rare occurrence. The purpose of the present 
study was to evaluate the efficacy and tolerability of combination chemotherapy 
with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for 
advanced thymic carcinoma. Methods:  A retrospective analysis of 34 untreated and 
unresectable thymic carcinoma patients who received chemotherapy with doxorubicin, 
vincristine, cyclophosphamide, and platinum compounds between 1996 and 2010 
was conducted. Twenty-nine patients were treated with a combination of cisplatin (50 
mg/m2) and doxorubicin (40 mg/m2) on day 1, vincristine (0.6 mg/m2) on day 3, and 
cyclophosphamide (700 mg/m2) on day 4. Five patients were treated with carboplatin 
(area under the curve of 3.0 min mg/mL) instead of cisplatin. Results:  The responses of 
all 34 patients to the current regimen were assessed. The median number of treatment 
cycles for the present chemotherapy was 4. The overall response rate and disease control 
rate were 50.0% and 88.2%, respectively. The median survival was 21.3 months (95% 
confidence interval [95% CI], 15.0–37.2 months), and the 1-year and 3-year survival rates 
were 72.7% (95% CI, 56.8–88.6%) and 34.4% (95% CI, 16.2–52.6%), respectively. The most 
common adverse event was leukopenia/neutropenia, and non-hematological toxicities 
were mild. Conclusion: Combination chemotherapy with doxorubicin, vincristine, 
cyclophosphamide, and platinum compounds is an effective and well-tolerated treatment 
for unresectable advanced thymic carcinoma
Keywords: chemotherapy, ADOC
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ITP-013: PRELIMINARY RESULTS FROM A PROSPECTIVE STUDY 
OF SYSTEMIC CHEMOTHERAPY WITH CARBOPLATIN PLUS 
AMRUBICINE FOR THYMIC MALIGNANCIES.
Akira Inoue1, Shunichi Sugawara2, Satoshi Oizumi3, Kunihiko Kobayashi4, Toshiyuki 
Kozuki5, Toshihiro Nukiwa1  
1Tohoku University Hospital, Sendai/JAPAN, 2, Sendai Kousei Hospital/JAPAN, 
3Hokkaido University/JAPAN, 4Saitama Medical University International Medical 
Center/JAPAN, 5Shikoku Cancer Center/JAPAN
Background: There has been no standard chemotherapy for advanced or recurrent thymic 
malignancies including thymic carcinoma (TC) and invasive thymoma (IT). Amrubicine 
(AMR), a new anthracycline agent, had been approved for lung cancer and we had previously 
conducted a few prospective studies of AMR combined with carboplatin (CBDCA) for 
patients with small-cell lung cancer, which revealed this regimen was active and safe for 
them. The objective of this study is to evaluate the efficacy and the safety of this combination 
for patients with thymic maligancies. Methods: Patients with histologically confirmed 
thymic malignancies received AMR (35 mg/m2, day1-3) and CBDCA (AUC 4.0, day1) every 
3 weeks. Patients who underwent previous chemotherapy received reduced dose of AMR (30 
mg/m2). The primary endpoint was overall response rate (ORR), and secondary endpoints 
were progression-free survival (PFS), overall survival and toxicity profile. Assuming that 
ORR of 45% and 75% would indicate potential usefulness while ORR of 20% and 50% 
would be the lower limit of interest, with alpha = 0.10 and beta = 0.20, for TC patients and IT 
patients, respectively. The estimated accrual was 20 each for TC and IT group. Results: From 
December 2008 to June 2012, 47 patients (29 TC and 18 IT) were enrolled from 18 institutions 
in Japan. Patients’ characteristics are as follows; male/female 32/15; median age 66 (range 
39-78); performance status 0/1 23/24. Among 11 patients with TC who had confirmed the 
response, 3 partial responses were observed. No treatment related death has been observed. 
Conclusion: AMR combined with CBDCA seems to be effective for patients with thymic 
malignancies with acceptable toxicities. Updated results will be presented at the meeting.
Keyword: amrubicine
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ITP-014: COMPARISON OF 5-FLUOROURACIL-RELATED GENE 
EXPRESSION LEVELS BETWEEN THYMIC CARCINOMA AND 
LUNG CANCER
Masayuki Chida, Hiromi Ishihama, Osamu Araki, Yoko Karube, Norio Seki, Makio 
Hayama, Satoru Kobayashi, Takeshi Oyaizu  
General Thoracic Surgery, Dokkyo Medical University, Mibu, Tochigi/JAPAN
Background: Because of the rarity of thymic carcinoma, biological features of thymic 
carcinoma are still uncertain. Methods: We investigated the 5-fluorouracil-related gene 
expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), 
thymidine phosphorylase (TP) in resected tumor specimens from 14 patients with thymic 
carcinoma, 49 patients with lung adenocarcinoma and 49 patients with lung squamous 
cell carcinoma using quantitative reverse transcription-PCR, and compared those levels 
between the two histological types. Results: The relative gene expression value of TS was 
significantly lower in lung adneocarcinomas compared with thymic carcinomas and lung 
squamous cell carcinomas, 1.60+0.86, 7.93+7.82 and 4.33+3.35 (P<0.001), respectively. The 
relative gene expression value of DPD was significantly greater in lung adenocarcinomas 
than those in thymic carcinomas and lung squamous cell carcinomas, 2.29+1.22, 1.14+0.95 
and 1.52+1. (P<0.01), respectively. The relative gene expression value of TP was significantly 
lower in lung adneocarcinomas compared with thymic carcinomas and lung squamous cell 
carcinomas, 9.52+6.30, 26.42+34.36 and 16.27+11.84 (P<0.01), respectively. Conclusion: 
The 5-fluorouracil-related gene expression levels of thymic carcinoma were similar to those 
of lung squamous cell carcinoma.
Keywords: thymic carcinoma, TS, DPD, TP
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ITP-015: THE RESULTS OF CHEMOTHERAPY AND/OR RADIA-
TION THERAPY FOR UNRESECTABLE OR RECURRENT THYMIC 
CARCINOMA – AN INSTITUTIONAL REPORT
Toru Kimura, Masayoshi Inoue, Masato Minami, Yasushi Shintani, Tomoyuki Nakagiri, 
Soichiro Funaki, Noriyoshi Sawabata, Meinoshin Okumura  
General Thoracic Surgery, Osaka University Graduate School Of Medicine, Osaka/
JAPAN
Background: Thymic carcinoma is a thymic epithelial neoplasm with more malignant 
features as compared to thymoma. Because thymic carcinoma presents with locally 
advanced disease or with distant metastasis, unresectable cases of this disease are 
frequently encountered at diagnosis. Therefore, systemic chemotherapy plays a key role 
in the treatment strategy for thymic carcinoma. Although cisplatin-based chemotherapy 
is usually administered for cases of thymic carcinoma, information on the optimal 
chemotherapy regimens or protocols is currently lacking. Methods: Seventeen consecutive 
patients with unresectable or postoperative recurrent thymic carcinoma treated between 
1996 and 2007 at the Osaka University Hospital were retrospectively reviewed. Results: 
Thirteen males and 4 females (median age, 59 years) were included in this study. The 
histological subtype of these cases included: squamous cell carcinoma in 11, small cell 
carcinoma in 2, large-cell neuroendocrine carcinoma in 2, poorly differentiated carcinoma 
in 1, and carcinoid in 1. The cases according to the Masaoka classification included 5 
with stage III, 4 with stage IVa, and 8 with stage IVb. Surgical resection was performed 
as the initial treatment in 8 patients; among these, 4 patients exhibited postoperative 
recurrence after complete resection. Chemotherapy was administered in 14 patients, 
including 6 patients who received combined radiotherapy. The therapeutic regimens were 
mainly platinum-based combinations including carboplatin+paclitaxel in 7 cases and 
cisplatin+docetaxel in 6 cases. The median number of administered regimens and cycles 
were 2 (range, 1-9) and 7 (range, 2-44) for each patient, respectively. The response rate/
disease-control rate of the first -line, the second-line, and the third-line settings were 
79%/93%, 60%/80%, and 0%/57%, respectively. Response rate tended to be higher in the 
patients who underwent chemoradiotherapy than in those who underwent chemotherapy 
alone. In patients with long survival, single-agent chemotherapy using taxanes or S-1 
might result in control of the disease even after the third-line regimen. The median 
survival was 36 months and the 1-, 3-, and 5-year survival rates were 81.9%, 55.5%, and 
23.1%, respectively. Conclusion: Thus, we suggest that combination chemotherapy with 
platinum compounds could be an effective treatment in patients with unresectable or 
recurrent thymic carcinoma. However, prospective multi-institutional studies required to 
ascertain the standard chemotherapy regimen for thymic carcinoma.
Keywords: thymic carcinoma, chemotherapy
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ITP-016: CHEMOTHERAPY FOR ADVANCED OR RECURRENT 
THYMIC CARCINOMA 
Tomoyoshi Takenaka1, Ryo Toyozawa1, Eiko Inamasu2, Miyako Kojo2, Goji Toyokawa2, 
Yoshimasa Shiraishi2, Yosuke Morodomi2, Fumihiko Hirai1, Masafumi Yamaguchi1, 
Takashi Seto1, Mitsuhiro Takenoyama1, Yukito Ichinose1  
1Kyushu Cancer Center, Fukuoka/JAPAN, 2Thoracic Oncology, Kyushu Cancer Center, 
Fukuoka/JAPAN
Background: Thymic carcinoma is a rare carcinoma of the thymus arising from the 
thymic epithelium. It has been difficult to conduct clinical trials for patients with 
thymic carcinoma because of the relatively low incidence of this disease; therefore, no 
standard chemotherapy has yet been established for this cancer. Methods: This study 
retrospectively examined the efficacy of chemotherapy in 18 patients with histologically 
diagnosed thymic carcinoma, Masaoka Stage IVa, IVb or postoperative recurrent disease 
who were treated at this institution. Results: Eighteen patients with thymic carcinoma 
underwent chemotherapy at this institution. The age of the patients ranged from 27 to 70 
years (mean, 56 years) including 9 males and 9 females. Poorly differentiated carcinoma 
including small cell carcinoma accounted for 50% (n =9), followed by squamous cell 
carcinoma (n=3), neuroendocrine carcinoma (n=2) and other histological types (n=4). 
The Masaoka Stage was stage IVa in 5 cases (28%), stage IVb in 10 (56%), and recurrent 
disease in 3 (17%). A carboplatin and paclitaxel regimen was administrated as the 
first-line therapy for 12 patients (67%) and another platinum based regimen (CODE, 
CDDP and CPT11, CDDP and vindesine) was administrated to 6 patients (33%). Eight 
and zero patients showed a partial response and complete response, respectively, 
representing a response rate of 44%. The median progression-free and overall survivals 
in all of the patients were 7.4 months and 19.3 months, respectively. In addition, the 
median progression-free and overall survival in the 12 patients received carboplatin and 
paclitaxel were 9.8 months and 21.7 months, respectively. Conclusion: A carboplatin 
and paclitaxel regimen is an alternative candidate for first-line therapy for patients with 
advanced or recurrent thymic carcinoma. Further prospective studies are warranted.
Keywords: thymic carcinoma, chemotherapy
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ITP-017: MANAGEMENT OF RECURRENT THMIC MALIGNACIES
Tatsuo Ohira1, Takefumi Oikawa1, Junichi Maeda1, Koichi Yoshida1, Yasufumi Kato1, 
Taichiro Ishizumi2, Masaru Hagiwara2, Hisashi Saji2, Masatoshi Kakihana1, Jitsuo 
Usuda1, Naohiro Kajiwara1, Masaharu Nomura1, Norihiko Ikeda1  
1Surgery, Tokyo Medical Universtiy, Tokyo/JAPAN, 2Surgery, Tokyo Medical University, 
Tokyo/JAPAN
Background: Thymic malignancies are rare epithelial tumors that may be aggressive 
and difficult to treat. Thymomas are usually localized to the anterior mediastinum and 
are frequently eligible for surgical resection. However, nearly 30% of patients present 
with locally advanced tumors at time of diagnosis, and chemotherapy is then used to 
reduce the tumor, possibly allowing subsequent surgery and/or radiotherapy. Metastatic 
and recurrent thymic malignancies may similarly be treated with chemotherapy. More 
recently, the molecular characterization of thymoma and thymic carcinoma led to the 
identification of potentially druggable targets, laying the foundations to implement 
personalized drugs for patients. It was reported that World Health Organization (WHO) 
histologic types AB or B1 and complete re-resection are favorable prognostic factors 
of recurrent thymoma. Complete resection of recurrent thymoma contributes to good 
survival. Thymomas showed sometimes recurrences over 10years after first operation. 
Therefore, it was reported that long-term surveillance extended at least 20 years may be 
essential for early detection of recurrence to increase the chance of complete re-resection 
of recurrent thymoma. According to NCCN guideline, standard chemotherapy for 
advanced thymoma was PAC therapy. PAC therapy was combination chemotherapy with 
Cisplatin, Doxorubicin and Cyclophosphamide. Some cases showed good response to 
S-1. 2-week method (2-week administration and 1-week withdrawal) for thymomas is 
feasible and effective. TS-1 is an oral anti-cancer agent for gastric, colon and lung cancer 
with a high response rate and low toxicity. Methods: commercially available in Japan. 
So, immunostaining was examined with these antibodies. Results: TS-1 showed good 
response in some cases. But, number of patients was small. We will show the data about 
immunostaning of TS, DPD, TP and OPRT in the conference. Conclusion: TS-1 may be 
included one of the chemotherapeutic drugs for thymic malignacies. But, there was not 
enough number of patients. Clinical trials including TS-1 would be expected. 
Keywords: thymoma, thymic cancer, TS-1
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ITP-018: EFFECTIVENESS OF AMRUBICIN FOR SECOND-LINE 
OR MORE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT 
THYMIC CARCINOMA.
Ryo Toyozawa, Humihiko Hirai, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, Yosuke 
Morodomi, Yoshimasa Shiraishi, Tomoyoshi Takenaka, Masafumi Yamaguchi, Takashi 
Seto, Mitsuhiro Takenoyama, Yukito Ichinose  
Department Of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka/JAPAN
Background: Thymic carcinoma (TC) is a rare mediastinal neoplasm with a poor 
prognosis. Although no chemotherapeutic regimen has yet been established for such 
patients, advanced TC has been treated with cisplatin and doxorubicin by using such 
regimens as ADOC or CODE. Patients with TC have frequently been treated by anti-cancer 
drugs used for patients with advanced non-small cell lung cancer. This study evaluated 
the efficacy and feasibility of amrubicin (AMR), a novel antrathycline anti-cancer drug, 
as a second-line or more chemotherapy against recurrent TC. Methods: The efficacy and 
toxicity of AMR for relapsed TC with prior platinum based combination chemotherapy 
were retrospectively evaluated. Results: Nine patients with recurrent TC were treated 
with AMR (35-40 mg/m2 day 1-3) as a second-line or more chemotherapy between June 
2003 and December 2011. The median age was 61 years (range 45-72), including 5 males 
and 4 femails, and all patients were in Masaoka’s Stage IVb. There were 3 squamous cell 
carcinomas, 1 adenocarcinoma, 1 small cell carcinoma, and 2 other histological types. 
The patients recieved an average of 6 cycles of chemotherapy (range2-21). Grade 3 or 
more toxicities included neutropenia (55.5%), anemia (25.0%), and febrile neutropenia 
(11.1%). no other serious adverse events were observed. The response rate to AMR was 
44.4% (4 partial response, 1 stable disease and 4 progressive disease). No treatment-related 
death was observed. Conclusion: AMR single agent therapy is therefore considered to be 
potentially effective as a second-line or more chemotherapy for patients with advanced TC. 
Further multi-institutional prospective studies are thus warranted.
Keywords: amrubicin, thymic cancer
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ITP-019: THE SAFETY OF POSTOPERATIVE RADIOTHERAPY FOR 
THYMOMA WITH MYASTHENIA GRAVIS- A STUDY OF 52 PATIENTS
Changlu Wang, Lanting Gao  
Radiation Oncology, Shanghai Chest Hospital, Shanghai/CHINA
Background: Myasthenia gravis (MG) is a common paraneoplastic syndrome of 
thymoma. About 30%-50% of all thymoma patients develop MG.MG is a kind of 
autoimmune disorder mainly associated with cortical subtype of thymoma (WHO type 
B) . Surgical resection remains the mainstay of treatment for thymoma patients with MG. 
Radical excision of a thymoma does in most cases cure the thymic neoplasia, but patients 
will continue to suffer from MG after thymectomy. Besides that, for some invasive or 
not completely resected cases, postoperative radiotherapy is demanded. Surgery and 
radiotherapy, however, are both stimulating factors that may exacerbate myasthenia 
syndromes. By far, there are few case reports discussing the impact of postoperative 
radiotherapy on MG. To make an overall evaluation of radiation influence on MG, we 
made a retrospective review of 52 patients who received adjuvant radiotherapy after 
surgery. Methods: From February 2002 to July 2011, totally 52 thymoma patients with 
MG underwent transternal thymectomy. Two patients developed MG after thymectomy, 
while the other 49 patients manifested MG preoperatively. All patients were diagnosed 
as thymoma by postoperative pathological examination with reference of WHO 
classification.All patients were treated with postoperative radiotherapy 4-8 weeks 
(average 5 weeks) after surgery. The dose of radiation ranged from 18Gy to 70Gy (mean 
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Definition of MG exacerbation: worsen of MG symptoms or appearance of MG crisis. The 
follow up time is more than 1 year Results: Nine patients developed MG exacerbation, two 
feamle patients died of MG crisis. Detailed information of 9 patients is in Table 2 
Information of nine patients developed MG exacerbation




1 M 47 B1 2 1 R0 70 S
2 F 60 B3 3 3 biopsy 24 U
3 M 52 B3 3 3 R2 56 U
4 F 45 B2 2 1 R0 50 S
5 F 65 B2 2 1 R0 50 U
6 F 72 B3 3 1 R2 18 U
7 F 63 B3 3 3 R2 18 U
8 M 60 B2 4a 2b R0 40 U
9 M 56 B3 3 2b R2 58 S
 
Note:* MG controlled pre-RT: S-satisfactory; U-unsatisfactory Case No 1 died of MG 8 
months after RT, case No 2 died 2 weeks after RT Multivariable factor analysis indicates 
that resection status of more than R2 (P=0.02)and uncontroled MG pre-RT(P<0.001) 
are high risk factors to induce MG exacerbation after RT. Conclusion: In general, 
postoperative radiotherapy is safe for thymoma with MG, but it shoud be carefully 
performed on those patients with residual tumor, and MG symptoms are highly 
recommended to be well controlled before and during the radiotherapy.Radiotherapy 
dose should be below 60Gy.
Keywords: thymoma, myasthenia gravis, Radiotherapy
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ITP-020: RESULTS OF SURGICAL INTERVENTION FOR STAGE IV 
THYMOMA
Masayoshi Inoue, Masato Minami, Noriyoshi Sawabata, Yasushi Shintani, Tomoyuki 
Nakagiri, Soichiro Funaki, Meinoshin Okumura  
Department Of General Thoracic Surgery, Osaka University Graduate School Of 
Medicine, Suita, Osaka/JAPAN
Background: The treatment strategy for stage IV thymoma with pleural dissemination 
or distant metastases is still controversial, while multimodality therapy including 
surgical resection is practically performed. The surgical role for such advanced thymoma 
remains unclear. Methods: We retrospectively analyzed 34 patients who underwent 
surgical resection of stage IV thymoma to evaluate its clinical significance.  Results: 
According to Masaoka stage, 23 stage IVa and 11 stage IVb patients were enrolled. 
Histological diagnosis was WHO type AB 2, B1 4, B2 16, and B3 12. Macroscopically 
complete resection was achieved in 16 patients, while partial resection including 
subtotal resection was performed in 18 patients. The 5-year and 10-year overall survival 
rates (5YS and 10YS) were 72.2% and 55.7%, respectively. According to the operative 
radicality, there was no significant survival difference between complete resection and 
partial resection (5YS: 76.2% vs. 68.5%). By Masaoka stage, 5YS was 87.3% and 42.9% for 
stage IVa and IVb, respectively, though no statistically significance was found. Neither 
gender nor age was detected as a prognostic factor.  Conclusion: In conclusion, long term 
survivors were observed in stage IV thymoma following complete or partial resection.
Keyword: thymoma, dissemination, surgery
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ITP-021: 40- YEAR FOLLOW-UP ANALYSIS OF CLINICAL AND 
PATHOLOGIC OUTCOMES OF THYMOMA
Stefano Cafarotti, Stefano Margaritora, Valentina Dall’Armi, Alfredo Cesario, Stefano 
Bonassi, Pierluigi Granone  
Thoracic Surgery, Catholic University Of Rome, Rome/ITALY
Background: With the unique opportunity of a 40-year follow-up in a single institution, 
we investigated the influence of early and long-term clinical predictors. Methods: We 
reviewed a surgical series of 305 (1970 to 2010) R0- patients with thymoma. Llinical and 
pathologic features were analyzed as prognostic factors matched against the short- and 
long-term and disease-free survival Results: Male/Female ratio was 1.03 (155/150), with a 
mean age was 49 ± 14 years, ranging from 8 to 84 years. According to Masaoka, 110 (36%) 
subjects were classified as stage I, 74 (24%) as stage II, 73 (24%) as stage III, and only 7 (2%) 
as stage IV; the remaining 14% could not be classified due to missing information. LTS and 
DFS between stage I and stage II did not differ (HRLTS= 0.97 [0.47;2.00], n.s.; HRDFS= 
1.46 [0.49;4.37], n.s.). Post-hoc pairwise comparisons showed statistically significant 
differences of LTS and DFS between stages II, III and IV, with HR’s ranging from 2.45 to 
14.43. Survival analysis based on the WHO-histology classification revealed as type A, AB, 
B1 and B2 had a similar and better LTS and DFS compared to type B3 and C. Statistically 
significant differences in LTS and DFS were found from a post-hoc analysis, where B3 
and C types were compared to type A, B1, B2, with HRs ranging between 3.06 to 18.59. 
Myastenia Cox regression analysis estimated statistically significant HRs for both LTS and 
DFS (Non-Myastenic vs Myastenic - HRLTS: 3.54 [1.76;7.14], p<0.001; HRDFS: 3.04 [1.43;6.47], 
p=0.004). Although myasthenia gravis had a strong impact on patients’ outcome, when 
a multivariable Cox regression analysis, including major prognostic predictors was 
performed, its impact lost statistical significance Conclusion: We confirm the evidence 
that the clinical staging and the histologic classification influence long-term survival.
Keyword: thymoma
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ITP-022: PREDICTORS FOR SURVIVAL IN PATIENTS WITH 
ADVANCED INVASIVE THYMOMA (STAGE III-IVA) OR THYMIC 
CARCINOMA (STAGE I-IV)
Daniel R. Gomez1, Andreas Rimner2, Pamela K. Allen1, Brad Greenfield1, Gregory J. 
Riely2, David Rice1, James Huang2, Kenneth E. Rosenzweig3, Ritsuko Komaki1  
1MD Anderson Cancer Center, Houston/UNITED STATES OF AMERICA, 2Memorial 
Sloan-Kettering Cancer Center, New York/NY/UNITED STATES OF AMERICA, 
3Mount Sinai Medical Center, New York/NY/UNITED STATES OF AMERICA
Background: Retrospective and prospective analyses have demonstrated promising 
survival rates in patients undergoing multimodality therapy for advanced invasive 
thymoma or thymic carcinoma. However, studies with large numbers of patients are 
sparse, particularly those comparing patients that received contrasting treatment 
regimens. We assessed prognostic factors for survival in patients undergoing treatment in 
this context, and compared those patients that completed trimodality therapy with those 
that received other regimens. Methods: We analyzed outcomes of 122 patients treated for 
Masaoka-Koga stage III-IVA invasive thymoma or stage I-IV thymic carcinoma treated at 
two tertiary oncologic referral centers from 1951-2011. The distribution of histologic type 
was as follows: stage III invasive thymoma, n=64 (52%), stage IVA invasive thymoma, n=24 
(19%), thymic carcinoma, n=34 (28%) (stage I, n=0; stage II, n=3; stage III, n=8; stage IV, 
n=21; unknown, n=2). The median age was 50 years (range 19.7-51). Ninety two percent of 
patients (n=112) underwent surgery. Chemotherapy was administered in 76% of patients 
(n=93), and 96% of patients received radiation therapy (RT) (n=117). The RT modality 
was: 2D/conventional, n=12; 3D conformal therapy, n=78; intensity modulated radiation 
therapy, n=27; unknown, n=5. Sixty six percent of patients (n=81) received trimodality 
therapy, most commonly induction chemotherapy followed by surgery, then postoperative 
RT (n=39). The second most common treatment regimen was surgery + RT (n=27). Kaplan-
Meier analysis was used to estimate survival outcomes, and Cox regression analysis was 
utilized to evaluate the prognostic impact of age, gender, histology, treatment regimen, 
and stage on disease-free survival (DFS), locoregional failure-free survival (LRFFS), 
distant metastasis-free survival (DMFS), and overall survival (OS). Results: At a median 
follow-up time for alive patients of 51.9 months (range 1.8-334.6 months), 5/10 year rates 
of DFS, LRFFS, DMFS and OS were 65/63%, 78/78%, 81/74%, and 73/50%, respectively. 
On univariate and multivariate analysis, patients with stage IVA thymoma (hazard ratio 
[HR]=1.96, p=0.0059) and with thymic carcinoma (HR=2.43, p=0.008) had significantly 
lower OS than patients with stage III thymoma. Patients with thymic carcinoma also had 
significantly reduced DFS (p=0.027, HR=2.36) and DMFS (p=0.006, HR=3.91) compared 
with stage III thymoma patients. There was no impact of histology/stage on LRFFS. When 
examining treatment regimen, there was a survival benefit of trimodality therapy when 
examining Stage III invasive thymoma patients with regard to OS (p=0.034) and DMFS 
(p=0.014), with a trend towards improvement in DFS (p=0.081) compared to patients 
who received less treatment (single or dual modality). Small patient numbers inhibited 
statistical comparison of treatment regimen in patients with stage IV thymoma or thymic 
carcinoma. Conclusion: Patients with advanced thymic malignancies can achieve long-
term survival with an aggressive treatment regimen, and most recurrences occur within 
the first 5 years. However, patients with thymic carcinoma have worse outcomes than those 
with Masaoka-Koga stage III-IVA invasive thymoma. We advocate a trimodality approach 
in eligible patients with either category of disease.
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ITP-023: WHO B3 THYMOMA: OPTIONS FOR TREATMENT  
CLINICAL OUTCOME
Harun Badakhshi1, Mahmoud Ismail2, David Kaul3, Tomasz Barelkowski1, Jens Rueckert2 
1Center For Cancer Medicine, Charite Medical School And University Hospital, Berlin/
GERMANY, 2Department For Surgery, Charite Medical School And University Hospital, 
Berlin/GERMANY, 3Radiology, Charite Medical School And University Hospital, Berlin/
GERMANY
Background: The WHO thymoma classification system had intruduced the well 
differentiated thymic carcinoma (WDTC) or WHO B3 group. It was described as a distinct 
organotypical carcinoma of the thymus with low-grade malignancy. It might have a more 
aggressive clinical course than other class B thyomas. We analysed our thymoma data 
base regarding treatment outcomes for WHO B3 thymomas.  Methods: From November 
1983 to June 2012, 138 patients with thymoma underwent tumor resection. We recorded 
prospectively for all patients since 1995 till present. For this study,merely “B3 type” were 
included. Medical records were reviewed details of operative procedures, location, tumor 
invasion as determined by the surgeon, histologic diagnosis, postoperative morbidity and 
mortality, and long-term follow-up. All patients were operated by the senior author of this 
paper. For the purpose of this study, we review the histology specimens by a central thymus 
pathology center Mannheim. Results: We could analyse 18 cases. The youngest patient 
was 18, the oldest 82 years old. Patients underwent a standardized pre-surgery procedure, 
containing team discussion and decision-making, thoracic imaging, pulmonary function 
tests. Decision leading to the surgical approach was based on general health situation, co-
morbidity, tumor size and patient preferences. Conventional sternotomy in 11 cases (61.1 
%), in 1 case (5.6 %) extended video-assisted thoracosopic thymectomy, and in 6 cases (33.3 
%) an extended robot assisted thoracosopic thymectomy. There was no intra-operative 
conversion. There was no operative mortality or major perioperative morbidity. One 
patient was admitted from the cardiology department with a preexisting cardiac failure, 
which was balanced at time of surgery. After surgery the cardiac situation aggravated 
and patient died on acute heart failure two weeks after surgery. A complete resection was 
possible in 17 cases (94.4%); in the remaining one case (5.6%), thymectomy was combined 
with a cardiosurgical procedure under complex conditions regarding cardiac problems, 
anesthesia. The surgical staging yielded in 2 cases (11.1 %) stage I, in 11 cases (61.1%) stage 
II, in 4 cases (22.2.%) stage III, and in 1 case (5.6%) stage IV thymoma. After a median 
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follow up of 78 months, the overall survival was 85 %, cancer specific survival at 5 years 
was 80 %. In 9 cases with stage II (n= 6) and III (n=3) a postoperative thorcic radiotherapy 
was applied. Int this group the rate of local contol at 5 years was 90%. Conclusion: Patients 
with WHO B3 thymoma might be considered as a subgroup with aggressive biologic 
behavior. Results of the current study are so far limited due to the retrospective mode of 
data analysis and the limited number of patients. However, in respect to local conrol and 
cancer specific survival, this study does not confirm data from literature. A larger cohort, 
and a multicenter pooled analysis of results may reveal more conclusive data.
Keywords: thymectomy, Radiotherapy, WHO B3, thymoma
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ITP-024: INDUCTION THERAPY FOLLOWED BY SURGERY FOR 
ADVANCED THYMIC CARCINOMA
Yasushi Shintani, Soichiro Funaki, Tomoyuki Nakagiri, Masayoshi Inoue, Noriyoshi 
Sawabata, Masato Minami, Meinoshin Okumura  
General Thoracic Surgery, Osaka University Graduate School Of Medicine, Osaka/
JAPAN
Background: In advanced stage thymic carcinoma complete surgical resection is not 
always achievable because local regional invasion of nearby organs by thymic carcinoma 
is very common. These lesions are often found as advanced disease classified in stage III or 
IV of the Masaoka staging system, thus multimodality treatment may increase resectability 
and reduces the incidence of local and systemic relapses. Methods: Between 2000 and 
2012, 12 patients with thymic carcinomas were considered not radically resectable at 
preoperative workup, thus received induction chemotherapy or chemoradiotherapy 
followed by surgery. According to the Masaoka system, 4 were stage III, 2 were stage 
IVa, and 6 were stage IVb preoperatively. Each patient received chemotherapy such as 
carboplatin/paclitaxel-based chemotherapy (n=4) or adriamycin/cisplatin/vincristine/
cyclophosphamide (ADOC) (n=1). 6 patients received cisplatin/docetaxel or CDDP/VP-
16-based chemotherapy and concurrent radiotherapy directed at the tumor and tumor 
invaded nodes at doses greater than 40 Gy. Results: The patients enrolled in this study 
consisted of 9 males and 3 females, ranging in age from 32 to 73 years (average, 54 years 
old). Pathology revealed 10 squamous cell carcinomas (SCC) and 2 others. Complete 
pathological response by the tumor was found in 11 patients No perioperative mortality 
was recorded. Nine (75%) had complete resection (CR) and 3 (25%) incomplete resection 
(IR). Complete pathological response by the tumor was found in 2 patients. In 4 cases the 
tumor was resected along with the superior vena cava followed by vascular reconstruction. 
In 1 patient, right brachiocephalic aretry was resected and reconstructed. Seven of the 
11 patients also underwent pulmonary resection or lobectomy due to involvement of 
pulmonary parenchyma. All procedures were performed via median sternotomy with 
assistance of video thoracoscopy or thoracotomy. Seven patients were alive after a median 
follow-up period of 3.6 years and the overall 5-year survival rate was 56%. During follow-
up, 6 of 10 patients with CR developed tumor recurrence (pleural dissemination n=2, neck 
lymph node n=2, pulmonary metastasis n=2). No statistical difference was found between 
stage III and IV disease (p = 0.40). The 5-year survival rate was 64% for CR disease and 33% 
for IR disease (p=0.03). Conclusion: Complete resection significantly increased survival 
rate, thus multimodality treatment may be a good treatment option for stages III and IV 
thymic carcinoma and provides high survival and acceptable recurrence rates. 
Keywords: multimodality treatment, thymic cancer
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ITP-025: COMPARISON OF SURGICAL APPROACHES FOR THYMIC 
DISORDERS: FEASIBILITY OF VATS THYMECTOMY AND COM-
PARISON WITH SMALL INCISION AND MEDIAN STERNOTOMY
Teng Mao1, Wenhu Chen1, Wentao Fang2  
1Department Of Thoracic Surgery, Shanghai Chest Hospital,Shanghai Jiaotong 
University, Shanghai/CHINA, 2Department Of Thoracic Surgery, Shanghai Chest 
Hospital, Shanghai/CHINA
Background: Surgical approaches for thymic disorders remain controversial. A large 
variety of approaches have been introduced, each with its advantages and disadvantages. 
The purpose of this study was to evaluate the feasibility and safety of video-assisted 
thoracoscopic surgery (VATS), and to compare surgical results of VATS with standard 
median sternotomy (MS) and other minimal invasive approaches through various small 
incisions (SI). Methods: One-hundred and eleven undergone surgery for thymic disorders 
(maximun diameter ≤ 5cm, clinical stage I-II for thymic tumors) during March 1, 2010 
to June 30, 2012 was retrospectively reviewed. Demographic characteristics, operation 
time, number and cause of conversion, blood loss during operation, duration and amount 
of chest tube drainage, transfusion, morbidity, and length of hospital stay (LHS) were 
compared between the three groups. Results: Of the 111 patients, 79 had thymic epithelia 
tumors (stage I 32, stage II 39, stage III 8), 31 had benign cysts and 1 had TB. Resection 
via VATS was carried out in 47 cases (including 3 robotic assisted cases), via SI in 26 cases 
(cervical incision, parasternal incision, or transverse sternotomy), and via MS in 38 cases. 
In the VATS group, there were 3 conversions among 38 cases through right-side approach, 
and 4 conversions among 9 cases through left-side approach. The causes for conversion 
included dense pleura adhesion, invasion of tumor into adjacent structures (pericardium, 
lung, or great vessels), and injury of the left inominate vein. There was no significant 
difference in operative time, blood loss or transfusion during operation, duration or 
amount of postoperative chest tube drainage among the 3 groups (p>0.05). Average LHS 
was significantly shorter in the VATS group (5.7 days) than in the SI group (7.5 days) and 
the MS group (8.2 days) (p <0.05).Total thymectomy was performed in 74 patients, 25 
(53.2%) in VATS cases, 11 (42.3%) in SI, and 38 (100%) in MS. The reset of the patients 
received tumor resection and partial thymectomy. Among all the subgroups, LHS was the 
shortest in VATS total thymectomy cases (5.0 days, p <0.05). There was no perioperative 
mortality. The only major morbidity was a postoperative bleeding necessitating 
reintervention in SI group. Conclusion: VATS for benign thymic lesions and early-stage 
thymic tumors is safe and feasible and was associated with shorter hospital stay compared 
with other minimal invasive approaches or standard sternotomy. In case of VATS, totally 
thymectomy is feasible and should be recommended for thymic tumors for shorter hospital 
stay and oncologic principles. Minimal invasive approaches via various small incisions 
may also be used for benign thymic lesions. Long-term follow-up results, incuding local 
recurrence, pleural implantation, and survival, are needed so as to evaluate the efficacy of 
VATS thymectomy for early-stage thymic tumors.
Keywords: minimally invasive thymectomy, thymoma, surgical approaches, VATS
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ITP-026: THYMIC CARCINOMA: 45 CASES AT A SINGLE INSTITUTION
Satoru Moriyama1, Motoki Yano2, Hidefumi Sasaki1, Yu Hikosaka1, Katsuhiro Okuda1, 
Masayuki Shitara1, Yoshitaka Fujii3  
1Oncology, Imunology, And Surgery, Nagoya City University, Nagoya/JAPAN, 
2Oncology, Immunology And Surgery, Nagoya City University Graduate School Of 
Medical Sciences, Nagoya/JAPAN, 3Oncology, Immunology And Surgry, Nagoya City 
University Graduate School Of Medical Sciences/JAPAN
Background: Thymic carcinoma is a rare mediastinal neoplasm that is often found 
locally advanced and/or with metastases. The clinical prognostic factors are not clear 
and the treatment has not been standardized. Methods: Forty-five patients with thymic 
carcinoma have been treated at Nagoya City University Hospital since 1983. The clinical 
and pathologic data of these patients were retrospectively reviewed. Results: There were 
25 males and 20 females, with a mean age of 59 years old. There were 30 squamous cell 
carcinomas, 6 neuroendocrine carcinomas, 3 adenocarcinomas, and 6 others. According 
to the Masaoka’s classification, 9 patients were diagnosed as clinical stage II, 17 stage III, 9 
stage IVa, and 10 stage IVb. Twenty cases were considered to be inoperable. Radiotherapy 
was given in 5 patients, chemotherapy in 4, and both chemotherapy and radiotherapy in 
11 inoperable cases. Twenty-five cases underwent resection. Microscopically complete 
resection was achieved in 14 patients, and incomplete resection in 11. Preoperative 
chemotherapy was given in 2 patients, and chemoradiotherapy in 5. Postoperative 
radiotherapy was given in 10 patients, chemotherapy in 3, and both chemotherapy and 
radiotherapy in 6. The median survival time and 5-year overall survival rates of all patients 
were 70 months and 58%, respectively. The median survival time and 5-year survival rates 
in stage II patients were - months and 85%, respectively, whereas those in stage III-IV were 
68 months and 53.7%, respectively. There was no significant difference in survival between 
the stage II and III-IV. Cases that underwent complete resection showed significantly 
better prognosis than cases with incomplete resection and inoperable cases (p = 0.03); 
median survival time and 5-year survival rates in complete resection cases were - months 
and 84%, respectively, whereas those in incomplete resection cases and inoperable cases 
were 47 months and 48%, respectively. Among the inoperable cases, those that received 
chemotherapy showed significantly better prognosis than cases with non-chemotherapy 
cases (p = 0.0002); the median survival time and 5-year survival rates in chemotherapy 
cases were 68 months and 53%, respectively, whereas those in non-chemotherapy cases 
were 4 months and 0%, respectively. Conclusion: The prognosis of thymic carcinoma is 
poor, but combined modality therapies with surgery, chemotherapy and radiotherapy may 
improve the prognosis.
Keyword: thymic carcinoma
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ITP-027: CLINICOPATHOLOGICAL CHARACTERISTICS AND 
PROGNOSTIC SIGNIFICANCE IN PATIENTS OF THYMIC  
CARCINOMA WITH SURGICAL TREATMENT
Tomohiro Haruki1, Tomoyuki Hishida1, Junji Yoshida1, Keiju Aokage1, Genichiro Ishii2, 
Yuichiro Ohe3, Kanji Nagai1  
1Division Of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa/JAPAN, 
2Pathology Division, Research Center For Innovative Oncology, National Cancer Center 
Hospital East/JAPAN, 3Division Of Thoracic Oncology, National Cancer Center Hospital 
East/JAPAN
Background: Thymic carcinoma is a rare neoplasm which presents at a locally advanced 
stage and has an aggressive behavior. Surgery plays a crucial role in the treatment 
of thymic carcinoma, however, it is also a fact that this disease often causes local 
recurrences or distant metastases after surgical treatment, regardless of complete 
resection. In this study, we aimed to evaluate clinicopathological characteristics and 
survival of thymic carcinoma treated with surgery. Methods: Between January 1992 
and December 2011, 136 consecutive patients underwent surgical resection for thymic 
epithelial tumors at our institution. Among them, 22 patients were diagnosed as having 
thymic carcinoma. We retrospectively reviewed clinicopathological characteristics and 
surgical outcomes of these 22 patients. The median follow-up period was 40 months. 
Results: There were 12 men and 10 women with a median age of 62 years. Among all 
patients, 12 patients (55%) were asymptomatic and were referred to our institution 
for their mediastinal abnormal shadows incidentally detected by chest X-ray or chest 
computed tomography. Fifteen patients (68%) were diagnosed by biopsy as having 
thymic malignant neoplasm preoperatively, and 5 patients (23%) received neoadjuvant 
chemotherapy with platinum based regimen. Eighteen patients (82%) underwent total 
thymectomy with combined resections of adjacent organ or disseminated lesions, 
and complete resection was achieved in 17 patients (77%). Histological diagnosis 
was squamous cell carcinoma in 18 (82%), adenosquamous carcinoma in 1, poorly 
differentiated carcinoma in 1, and combined squamous cell carcinoma in 2 (with 
thymoma in 1, and with large cell neuroendocrine carcinoma in 1). The distributions 
of Masaoka stage were I in 4 (18%), II in 2 (9%), III in 13 (59%), and IVb in 3 (14%), 
respectively. Among patients with available data, immunohistochemistries of CD5 and 
c-kit were positive for 11 (69%) in 16 patients and 11 (85%) in 13 patients, respectively. 
Lymphatic permeation was positive for only 3 (17%) in 18 patients. However, vascular 
invasion was positive for 13 (72%) in 18 patients. The 3-year overall and recurrence-
free survivals of all patients were 75.6% and 37.7%, respectively. In 17 patients who 
underwent a complete resection, no patients with Masaoka stage I-II recurred, but 10 
of 11 patients with stage III-IV developed recurrences during the follow-up period. The 
3-year recurrence-free survival of the patients with Masaoka stage I-II and III-IV after 
complete resection were 75.0% and 27.3%, respectively, and the difference was statistically 
significant between the 2 groups (p = 0.01). Conclusion: Although this is a retrospective 
analysis with small cohorts, it suggested that thymic carcinoma has a biologically 
malignant nature. However, a complete surgical resection appears to have favorable 
prognostic significances in cases of early-stage disease. Considering high incidence of 
recurrence in advanced stages even after complete resection, a multimodality approach 
consisting of perioperative chemotherapy or radiotherapy should be investigated. There 
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is an urgent need to establish optimal treatment strategies for especially advanced thymic 
carcinomas by large, multicenter studies.
Keywords: thymic carcinoma, Surgery
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ITP-028: RESULT OF SURGICAL RESECTION OF THYMIC  
CARCINOMA
Tsuyoshi Takahashi, Tomohiro Murakawa, Chihiro Konoeda, Junji Ichinose, Yuta Inoue, 
Haruaki Hino, Atsushi Sano, Kazuhiro Nagayama, Jun Nakajima  
Department Of Thoracic Surgery, The University Of Tokyo, Tokyo/JAPAN
Background: Thymic carcinoma is a rare type of mediastinal malignancy, and the optimal 
treatment option has not been established yet. There were some reports that complete 
surgical resection was associated with long-term survival. Methods: Retrospective chart 
review of patients who underwent a surgical resection of the thymic carcinoma from 1984 
to 2011. Results: There were 21 thymic carcinoma patients. One patient who had bone 
metastasis at presentation underwent only radiotherapy. There were 15 men and 6 women, 
with a mean age of 55 (range: 31-76). The median follow-up period was 55.5 months. 
Preoperative diagnosis was obtained in 10 cases, 9 by computed tomography guided needle 
biopsy and one by open biopsy. Mean tumor size was 5.7 cm (range: 1.4-17.0). Neoadjuvant 
treatment was administered to 4 patients (radiotherapy (RT) in 2, chemotherapy (CT) in 1, 
and chemoradiotherapy (CRT) in 1). Complete response was seen in one patient whose 
histological subtype was small carcinoma, partial response in 1 patient and stable disease 
in 2 patients. The histological subtypes were squamous cell carcinoma in 14 patients, 
adenocarcinoma in 2, undifferentiated carcinoma in 2, small cell carcinoma in 1, basaloid 
carcinoma combined with lymphoepithelial-like carcinoma in 1, unclassifiable in 1. The 
distribution of Masaoka-Koga stage I / II / III / IVa / IVb; 2 / 5 / 7 / 2 / 5, respectively. Of 20 
patients who underwent surgery, complete resection was achieved in 12 patients, 
incomplete resection in 7 patients and only biopsy in 1 patient. There were no perioperative 
deaths. Adjuvant treatment was administered to 15 patients (RT in 11, CT in 3, and CRT in 
1). The 5-year overall survival rate of all patients was 52%. The patients who underwent 
complete surgical resection had significantly good prognosis (5-year overall survival: 
complete resection 72% vs incomplete resection 18%, p=0.035). 
 
Conclusion: Thymic carcinoma tended to present with locally advanced disease. 
Survival of patients with thymic carcinoma was relatively poor. Complete resection 
seems to be essential for obtaining long-term survival. The role of RT/CT/CRT remains 
unclear from this study. 
Keywords: thymic carcinoma, surgical resection
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ITP-029: THORACOSCOPIC THYMECTOMY FOR THE SURGERY 
OF THYMOMA
Arif K. Allakhverdiev, Konstantin Laktionov, Mikhail Davydov  
Thoracic Surgery, Russian Cancer Research Center, Moscow/RUSSIAN FEDERATION
Background: Traditionally, thymectomy for thymic tumors has been performed using 
either a transcervical approach or a median sternotomy. However, excision of the thymic 
tissue by thoracoscopic surgery is less aggressive and recovery is faster. The aim of 
this study was to evaluate the usefulness and outcomes of thoracoscopic thymectomy. 
Methods: From 2007 to 2011, we have performed 51 thoracoscopic thymectomies on 
patients with noninvasive stage I thymoma. This study included 20 women and 31 men, 
with a mean age of 49.1 years. Right-side (30 cases) or left-side (21 cases) thoracoscopic 
surgery was performed, with a mean intervention time of 105 minutes (range, 60-180 
minutes). Results: No patient required assisted ventilation for more than 4 hours and the 
maximum stay in intensive care was less than 24 hours. Mean chest tube drainage time 
was 1,75 days and mean postoperative hospital stay was 4,55 days. There was no mortality. 
More than 50 % of patients are observed about 3th years, and given for progressing of 
disease not received Conclusion: Thoracoscopic thymectomy is effective in the treatment 
of thymic tumors and improves patient recovery. Videoendoscopy ensures optimal 
exposure of the mediastinum, safe and complete bilateral dissection of the thymus as 
well as the surrounding tissues. Preliminary results of videoendoscopic thymectomy for 
noninvasive stage I thymoma suggest this may be the treatment of choice. Further data and 
larger series are needed to evaluate long-term results.
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ITP-030: OUTCOME OF AN ORIGINAL VIDEO-ASSISTED  
THORACOSCOPIC EXTENDED THYMECTOMY FOR THYMOMA
Sadanori Takeo  
Division Of General Thoracic Surgery, Respiratory Center And Clinical Institute, 
National Hospital Organization Kyushu Medical Center, Fukuoka/JAPAN
Background: Minimally invasive surgery using thoracoscopy has become a popular 
surgical technique for the removal of lung and mediastinal tumors. If minimally 
invasive surgery using thoracoscopy can be performed to the same extent as surgery 
with a transsternal incision, then the functional and cosmetic advantages for the patient 
are considered to be unquestionable. However, video-assisted thoracoscopic extended 
thymectomy (VATET) in a patient with a thymoma larger than 5 cm in size is still 
technically difficult because of the lack of appropriate techniques and the narrow space in 
the anterior mediastinum. We previously reported an original method (1) that gave a wide 
field of vision between the sternum and heart. The objective of this study was to evaluate 
the feasibility and outcome of VATET using this original sternum-lifting technique in 
patients with thymoma. Methods: Minimally invasive surgery using thoracoscopy has 
become a popular surgical technique for the removal of lung and mediastinal tumors. 
If minimally invasive surgery using thoracoscopy can be performed to the same extent 
as surgery with a transsternal incision, then the functional and cosmetic advantages for 
the patient are considered to be unquestionable. However, video-assisted thoracoscopic 
extended thymectomy (VATET) in a patient with a thymoma larger than 5 cm in size is 
still technically difficult because of the lack of appropriate techniques and the narrow 
space in the anterior mediastinum. We previously reported an original method (1) that 
gave a wide field of vision between the sternum and heart. The objective of this study 
was to evaluate the feasibility and outcome of VATET using this original sternum-lifting 
technique in patients with thymoma. Results: All patients successfully underwent VATET, 
and none required conversion to a median sternotomy. Two patients also underwent 
partial resection of the lung and pericardium. While there were no perioperative deaths, 
3 patients developed minor complications. The average tumor size was 5.2 cm. Fifteen 
tumors were larger than 5 cm. Pathologically, 15 were Masaoka` s Stage I, 19 were Stage II, 
and 1 was Stage III. There were no significant differences in the tumor size between Stages 
I and II. There were 2 Type A, 8 Type AB, 15 Type B1, 5 Type B2, 3 Type B3 and 2 thymic 
carcinomas. Twenty tumors were located in the right body, 5 were in the middle and 10 
were on the left. There were no differences in the tumor size or pathological stage according 
to location. There were also no differences in the pathological stage according to the tumor 
size. The average follow-up period was 65 months. One patient showed recurrence to the 
bilateral lung 3.5 years after surgery. After resection, this patient has been free of disease as 
of 5 years after the first surgery. There has been no recurrence in any of the other patients. 
Conclusion: Our original VATET procedure may be indicated for patients with clinical 
Masaoka’s Stages I and II, and in those with tumors larger than 5 cm in size.
Keywords: thymoma, Extended thymectomy, lift -up sternum
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ITP-031: MINIMALLY INVASIVE THYMECTOMY - THE WAY AHEAD?
George Karimundackal, Sabita Jiwnani, C S. Pramesh  
Surgical Oncology, Tata Memorial Hospital, Mumbai/INDIA
Background: Median Sternotomy has long been the standard approach for excision of 
thymomas. However this approach entails a significant amount of morbidity. Infact 
most of the morbidity associated with the procedure is related to the approach. Video 
assisted thoracoscopic surgery allows an equally effective resection with very little 
morbidity Methods: We conducted a retrospective analysis of all the cases of thymoma 
which underwent resection in our hospital in the past four years. We compared the 
mean operative blood loss, mean operative time and the median hospital stay between 
the patients who underwent an open procedure ie median sternotomy and video assisted 
thoracoscopic surgery Results: In the time period between June 2008 to June 2012, thirty 
four cases of thymoma underwent resection in our institute. In thirty three cases an R0 
resection was achieved. There was a significant trend towards VATS excision with time, 
2/15 in the first two years vs 11/18 in the latter two years. The mean operative time was 
almost similar in the two groups, 136 minutes in the VATS group vs 130 minutes in the 
open group. However the the mean blood loss in the VATS group was significantly less 
than the open group, 126.9 ml vs 668.5ml, p=0.018. The median duration of hospital 
stay was 4 days in the VATS group versus 5 in open surgery group. There was no major 
morbidity in either of the groups Conclusion: Video assisted thoracoscopic surgery is 
a fast developing field and provides a much less morbid approach to excision of thymic 
masses. We accept that the data as presented in our retrospective study may be inherently 
biased with the larger and more complex cases undergoing open surgery. However 
the significant reduction in blood loss and hospital stay may atleast in part be due to 
the minimally invasive approach. As surgeons grow in experience with the minimally 
invasive approach, there might be a similar decrease in operative times also. We propose 
that video assisted thoracoscopic excision of thymoma should be attempted wherever 
feasible with open surgery being reserved for more complex tumours
Keywords: VATS, thymoma
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ITP-032: RELATIONSHIPS AMONG THE WHO HISTOPATHOLOGI-
CAL CLASSIFICATION, THE MASAOKA STAGING SYSTEM AND 
TUMOR DIAMETER IN SURGICALLY RESECTED THYMOMAS
Mikihiro Kohno1, Tatsuro Okamoto1, Hirokazu Kitahara1, Shinichiro Shimamatsu1, 
Tsukihisa Yoshida1, Kenichi Suda1, Kayo Ijichi2, Takaomi Koga2, Tokujiro Yano3, 
Yoshihiko Maehara1  
1Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu 
University, Fukuoka/JAPAN, 2Division Of Pathophysiological And Experimental 
Pathology, Department Of Pathology, Graduate School Of Medical Sciences, Kyushu 
University, Fukuoka/JAPAN, 3Clinical Research Institute, National Beppu Medical 
Center, Beppu/JAPAN
Background: The Masaoka Staging System is closely correlated with survival in many 
studies. A systematic review of the literature showed that the World Health Organization 
(WHO) histopathological classification reflects the prognostic value, although some 
papers have reported that it is not a good indicator of the progression or malignant 
potential. Few studies have focused on the correlations between the WHO classification 
and the Masaoka staging system. The purpose of the present study was to retrospectively 
investigate the relationship between the WHO classification, the Masaoka staging system 
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and tumor diameter and clarify the contribution of the WHO classification to the 
clinical presentation and prognosis. Methods: Seventy-five patients underwent surgical 
resection for thymoma at our department in Kyushu University Hospital from January 
1991 to December 2011. This study retrospectively examined the correlation of the WHO 
histopathological classification with the Masaoka staging system, the maximum tumor 
diameter and other clinicopathological variables. Results:  Table 1 shows the relationship 
between the WHO histopathological classification and the Masaoka staging system.  
 
Fisher’s exact test shows WHO type B2 or B3 to significantly correlate with the 
progression of the Masaoka staging system (p=0.012). The mean maximum tumor 
diameter of type A, AB, B1, B2, B3 was 6.9 ± 1.8, 5.8 ± 0.6, 5.3 ± 0.5, 6.2 ± 0.5, 7.3 ± 1.1 
cm, respectively. The tumor diameter of type B2 or B3 thymoma was larger than that of 
type A, AB or B1, although the difference was not significant (p=0.12). The mean 
maximum tumor diameter of Masaoka stage I, II, III, IVa, IVb was 5.4 ± 0.4, 5.5 ± 0.4, 9.4 
± 1.7, 9.0 ± 2.0, 6.6 ± 0.1 cm, respectively. Thymomas with a larger tumor size 
significantly correlated with the progression of the Masaoka stage (p=0.016). A 
multivariate analysis for postoperative disease-free survival (DFS) demonstrated only 
the Masaoka staging system to be an independent prognostic covariate (p=0.037). 
Conclusion: A significant relationship was observed between the WHO 
histopathological classification and the Masaoka staging system. However, only the 
Masaoka staging system demonstrated a prognostic significance for DFS.
Keywords: WHO histopathological classification, thymoma, Masaoka staging system
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ITP-033: SHORT AND LONG-TERM FOLLOW-UP OF PATIENTS 
WITH THYMOMA AFTER SURGICAL RESECTION: A SINGLE 
INSTITUTION EXPERIENCE
Stijn R.G. Heyman1, Katrien Van Kolen1, Laurence Pierrache1, Bram Balduyck1, Rudy 
Mercelis2, Jeroen Hendriks1, Patrick Lauwers1, Paul Van Schil1  
1Thoracic And Vascular Surgery, Antwerp University Hospital, Edegem/BELGIUM, 
2Neurology, Antwerp University Hospital, Edegem/BELGIUM
Background: Thymomas are the most common tumors in the anterior mediastinum. 
Methods: We retrospectively reviewed 42 patients with thymoma from 1993 to 2011. 
The objective was to evaluate short- and long-term follow-up, clinical outcomes and 
pathological features after surgical resection. All thymomas were staged according to 
the Masaoka-Koga classification : stage I (16), stage IIa (14), stage IIb (7), stage III (4) 
and stage IVa (1), . and according to the WHO classification: A (8), AB (12), B1 (6), B2 
(9), B3 (5) and micronodular growth (2). Results: In our population sex distribution 
revealed 22 females and 20 males, 16 patients had myasthenia gravis. Diagnostic work-
up incorporated a CT scan for myasthenia gravis (12), thymoma related symptoms (8), 
tumor staging (4) or other pathology (infection, trauma, ...) (14). All patients underwent 
surgical resection using: median sternotomy (23), anterolateral thoracotomy (8), clam 
shell (2), and VATS (9). We administered adjuvant radiotherapy in 17 patients or 
chemoradiotherapy in 1 patient after R1-resection. During follow-up, mortality was 
observed in 2 patients and relapse in 2 patients (pleural & mediastinal). Conclusion: 
Five-year overall survival rate was 91.3% and 10-year survival 83.3%. Regression 
analysis showed that only cardiac comorbidities had a significant effect on length 
of hospitalisation (p = 0.013). There were no significant differences in prevalence of 
myasthenia gravis between WHO stages (p = 0.124) or Masaoka stages (p = 0.165). There 
was a significant difference in AchRab value and relapse of thymoma (p = 0.002). 
Keywords: long-term follow-up, surgical resection, thymoma
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ITP-034: CLINICAL FEATURES OF THYMIC EPITHELIAL  
TUMORS; EXPERIENCE OF ONE CENTER IN KOREA
Min Ki Lee1, Mi Hyun Kim2, Chang Hun Lee1, Young Dae Kim1, Ho Seok Lee1  
1Pusan National University Hospital, Busan/KOREA, 2Pusan National University 
Hospital, /KOREA
Background: Thymic epithelial tumors are the most common tumors affecting anterior 
mediastinum. The aims of this study is to investigate the clinical features of patients who 
diagnosed of thymic epithelial tumors at one university hospital in Korea. Methods: 
The clinical records are collected and reviewed retrospectively to the patients who 
were diagnosed of thymic epithelial tumors at Pusan National University Hospital in 
Korea for 10 years. The pathologic classification and clinical stages of thymic epithelial 
tumors were based on WHO classification and Masaoka’s staging system. Results: Total 
37 patients were reviewed and 23 patients were male. The mean age was 51.3 years old. 
Initial symptoms of the patients were reviewd and their symptoms were as follows : chest 
pain (53%), dyspnea (23%), cough (16%). Myasthenia gravis was diagnosed in 5 patients. 
With respect to tumor staging, 3 patients (8%) were stage I, 10 patients (28%) were stage 
II, 12 patients (32%) were stage III, 6 patients (16%) were stage IVa and 6 patients (16%) 
were stage IVb. 24 patients (67%) had stage III or IV diseases. The pathological types 
according to the WHO classification were as follows : A (3%), B1 (32%), AB (6%), B2 
(16%), C (23%). Operation was done for 24 patients and during follow-up, 4 patients were 
relapsed. Conclusion: In this retrospective review of thymic epithelial tumors, stage III 
or IV disease and WHO type B3 or C were common at diagnosis. And result of these 
characteristics may contribute to postoperative recurrence and poor outcome.
Keywords: thymic epithelial tumor, thymoma
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ITP-035: THYMIC CARCINOMA: SINGLE INSTITUTIONAL  
EXPERIENCE WITH 10 PATIENTS IN RECENT 11 YEARS
Masatoshi Kakihana  
First Department Of Surgery, Tokyo Medical Universtiy, Tokyo/JAPAN
Background: Thymic epithelial tumours, the most common tumour of the anterior 
mediastinum, are epithelial neoplasms of the thymus with a wide spectrum of 
morphologic features. Thymic carcinoma (TC) is a rare neoplasm with extremely poor 
prognosis.The controversies in classifications of thyimic epitherial tumors are unsettled 
at this time. We retrospectively analysed the clinical features of TC and 
investigated the prognostic impact of the WHO histotype, Masaoka’s staging system 
and the complete resectability in a series of patients with TC over a period of 11 years 
at a single institution. Methods: We retrospectively analysed clinical features of TC 
and the correlation of World Health Organisation (WHO) histologic classification and 
Masaoka staging system with different treatment modalities in 10 patients, from 2001 
to 2011. Results: Patients with completely resected types B2, B3 and TC and adjuvant 
radiotherapy had more favourable disease-free and overall survival as compared with 
those without adjuvant treatment. Conclusion: Our data show that complete resection, 
postoperative radiotherapy, and squamous cell carcinoma tend to indicate favorable 
results. Positive trend of favorable outcome in patients who received complete resection 
is ambiguously shown.
Keywords: thymic carcinoma, thymic epitherial tumors
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ITP-036: INTRA-TUMOR PRESSURE OF THYMOMA
Takeshi Mori, Tatsuya Yamada, Yasuomi Ohba, Kentaro Yoshimoto, Koei Ikeda, Kenji 
Shiraishi, Makoto Suzuki  
Thoracic Surgery, Kumamoto University Hospital, Kumamoto/JAPAN
Background: Intra-tumor pressure (ITP) was reported to be one of prognostic factors 
for head and neck cancer and hepatocellular carcinoma (HCC). A capsule of HCC was 
thought to elevate ITP. Thymoma usually has prominent capsule as well as HCC does. 
The aim of this study is to evaluate clinical effectiveness of measuring ITP of thymoma. 
Methods: After institutional review board approval, from March 2010 to Apr 2012 we 
conducted to measure ITP of 14 cases of thymomas, 4 male and 11 female with mean 
age of 60 year-old (40-71). The histological types of 14 thymomas according to WHO 
classification are as follows: type A (1), type AB (4), type B1 (5), type B2 (2), and with 
B3 (1), respectively. The distributions of stages of 14 patients of thymoma according 
to Masaoka system are as follows: stage I (2), stage II (9), stage III (2), stage IV (0), 
respectively. ITP was measured was measured using a micro catheter pressure transducer 
(Millar Instruments Inc.) in a manner similar to that described by an earlier report. The 
probe (SPR-1000 1F pressure transducer) which was coupled to an infusion 23½ gauge 
needle was introduced into the resected thymoma. The metal guide was withdrawn 
slowly, while the sensor is introduced into the center of the tumor. Then ITP was 
measured. Results: Mean ITP was 11.3±5.1mmHg (5.3　21.0). There was no relationship 
between ITP and tumor size (r=0.124). Mean ITPs of Masakoka I, II, III thymomas 
were 14.8±5.1, 11.9±5.0, 7.0±2.3 mmHg. ITP of type B1, B2 thymoma (15mmHg) was 
significantly higher than ITP of other type of thymoma (7.2mmHg) (p=0.012). 
 
 
APLCC/ITMIG 2012 Abstracts  Volume 7, Number 11, Supplement 5, November 2012
S429  Copyright © 2012 BY THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Conclusion: ITP of thymoma did not correlate with tumor aggressiveness of thymoma. 
Type B1 or B2 thymoma showed higher ITP than other type of thymoma did.
Keywords: intra-tumor pressure, thymoma
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ITP-037: CLINICAL OUTCOMES OF VIDEO-ASSISTED THORACO-
SCOPIC BILATERAL EXTENDED THYMECTOMY FOR MYASTHE-
NIA GRAVIS
Hyo Yeong Ahn1, Hoseok I2, Yeong Dae Kim2, Jeong Su Cho2  
1Pusan National University Hospital, Busan/KOREA, 2Pusan National University 
Hospital/KOREA
Background: The extended thymectomy for patient with myasthenia gravis (MG) has 
been reported to have clinical remission rate up to 80%. This study was determined to 
assess the changes in clinical symptom of patients diagnosed with MG treated with 
video-assisted thoracoscopic bilateral extended thymectomy. Methods: 21 patients 
diagnosed with MG underwent video-assisted thoracoscopic bilateral extended 
thymectomy at Pusan National University Hospital from January 2006 to December 
2011. Almost of them (n=15) had presence of a thymoma as diagnosed by computed 
tomography and six of them had persistent MG symptom while on medical regimen. 
The patients were subgrouped into the worsened (WG) and improved group (IG). We 
reviewed the factors influencing the outcome are clinical status and medical requirement 
at preoperative and last postoperative follow-up, age, sex, duration of disease, Masaoka 
and WHO classification of existing thymoma, follow-up duration, time elapsed between 
diagnosis and operations, and coexistent medical condition. Mann-Whitney U test, 
Pearson’s chi square test, Fisher’s exact test were used for statistical method to compare 
the variable between groups. Results: The mean age of 21 patients (11 patients were 
male) was 49.5± 11.2 -years-old. There were 6 patients in IG (remission in three patients 
and improvement in three patients) and 15 patients (71.4%) in WG. The median time 
elapsed between diagnosis and operation was 1.5 months (range, .5 ~ 34.3 months) 
and the median follow-up duration was 24.9 months (range, .7 ~ 56.2 months). Of 20 
patients whose preoperative symptomatic classification could be found, 13 patients 
were in Osserman stage I, 6 patients in stage II, and 1 patient in stage III. Post-operative 
pathologic study of thymus revealed normal tissue in one patient, hyperplasia in five 
patients, infarcted thymoma due to preoperative pulse steroid therapy in one patient, 
WHO type B1 in one, B2 in 12, and B3 in one patient. There were Masaoka I stage in 4, 
IIa in 8, IIb in 1, and III in 2 patients. The preoperative Osserman stage, age, sex, time 
elapsed between diagnosis and operations, Masaoka stage, and WHO classification of 
thymoma were not found to be statistically significant between groups. Conclusion: 
Our study demonstrated video-assisted thoracoscopic extended thymectomy was 
yet controversial for treatment of choice in patient with MG. So another option, such 
as extent of thymectomy and modality of thymectomy, in patients with MG might 
be investigated and a prospective trial for long term follow-up could be essential to 
determine a benefit of video-assisted thoracoscopic extended thymectomy in patient 
with MG.
Keywords: thymectomy, myasthenia, thymoma, Surgery
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ITP-038: THE PRESENCE OF MYASTHENIA GRAVIS INFLUENC-
ING PATHOLOGICAL AND CLINICAL CHARACTERISTICS OF 
THYMOMAS
Lei Yu1, Yun Jing2, Shan Ma1  
1Department Of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, 
Beijing City/CHINA, 2Department Of Neurology, Beijing Tongren Hospital, Capital 
Medical University, Beijing City/CHINA
Background: The objective of this study was to evaluate the different pathological and 
clinical characteristics of thymomas with and without myasthenia gravis (MG) and 
determine whether the presence of MG influences the prognosis in thymoma patients. 
Methods: We retrospectively studied data from 228 consecutive patients operated on 
from1992 to 2007. These thymoma patients have been subdivided into two groups: 
thymoma with MG (n=125) and thymoma without MG (n=103). All thymic epithelial 
tumors were classified according to the WHO histologic classification and the Masaoka 
clinical staging system. Results: There were no peri-operative deaths. 19 cases were 
inoperable. (6 in the group with MG, 13 without MG, P=0.035). The proportions of type 
A and thymic carcinoma in this data were 0% in the group with MG, 10.5% and 11.6% 
respectively in the group without MG. According to the Masaoka’s clinical staging, in 
the group MG, 24.8 % patients were stage III and IV; in the group without MG, 33 % 
patients were stage III and IV. There was a significant difference between hyperplastic 
paraneoplastic thymus coexisting in 28.8% patients with MG and only 5.8% in patients 
without MG. Microthymoma was identified in the paraneoplastic thymus of 3 patients 
with MG. There were 198 patients followed up. There was no recurrence in patients with 
type A and a few patients with type AB, B1, B2, B3 thymoma and thymic carcinoma 
recurred. The actuarial 5- and 10-year survival rates were 89.3% and 81.2% for patients 
with MG respectively, and 90% and 78.9% for patients without MG respectively. Within 
5 years postoperatively, 6 of 9 patients with MG died of myasthenia crisis, while 6 out of 
7 deaths in patients without MG were attributable to inoperable tumors (stage IV) and 
thymic carcinoma. Conclusion: MG seldom occurs in type A and thymic carcinoma. 
The existence of myasthenia gravis has little influence on the prognosis of thymomas. 
Extended thymectomy should be performed to all patients with thymoma. The main 
cause of death is myasthenia crisis for thymoma patients with MG and stage IV and /or 
thymic carcinoma for patients without MG.
Keywords: Characteristics, outcome, thymoma, myasthenia gravis
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ITP-039: SURGICAL RESULTS OF MYASTHENIA GRAVIS WITH 
THYMOLIPOMA
Chien Sheng Huang, Po-kuei Hsu, Chih-cheng Hsieh, Yu-chung Wu, Biing-shiung 
Huang, Wen-hu Hsu  
Division Of Thorcic Surgery, Department Of Surgery, Taipei Veterans General Hospital, 
Taipei/TAIWAN
Background: Thymolipoma, composed of mature adipose tissue and benign 
thymic tissue, is a slow growing benign mediastinal tumor. Although removal of 
the thymolipoma following by significant improvement of myasthenic symptoms 
had been reported in the literature, the relationship between the thymolipoma and 
myasthenia gravis remains unknown. The aim of this study is to review the surgical 
results of myathenic patient with thymolipoma in a single institute. Methods: Medical 
records for patients who underwent extended thymectomy for myasthenia gravis from 
January 1995 to December 2010 in Taipei Veterans General Hospital database were 
retrospective reviewed. The clinical demographic characteristics of the patients such 
as age, gender, preoperative myasthenic severity, anti-acetylcholine receptor antibody 
level, chest computed-tomography (CT), surgical approaches, postoperative histologic 
type of tumor(s) and improvement of myasthenic symptoms were abstracted for further 
analysis. Results: There were 283 myathenic patients underwent extended thymectomy 
during this period. A total of 12 patients (4.2 %) were histologically diagnosed as 
thymolipomas, including 7 male patients and 5 female patients, with a mean age of 54.4 
years (range 34-80). The symptom duration before operations was from 1 to 180 months 
with a mean of 53.4 months. Preoperative MG severity was class I in 4 patients, class IIa 
in 1 patient and class Iib in 7 patients. Only 3 patients had fat hyperplasia diagnoses from 
the chest CT preoperatively. 7 patients (58.3%) received preoperative steroid treatment. 
The removal of thymic and adipose tissue was from 38 to 250 gm with a mean of 119 gm. 
10 patients underwent transsternal extended thymectomy and the other two received 
right-sided video assisted thoracoscopic extended thymectomy. No perioperative 
complications either postoperative exacerbation of myasthenia gravis were noted for all 
patients with thymolipoma. There was also no tumor recurrence during postoperative 
follow-up. Complete remission was achieved in 5 of 12 patients (41.7%) and marked 
clinical improvement in 6 patients (50%). One patient was in symptomatic unchanged. 
The total improvement rate was 91.7%.  Conclusion: It is difficult to diagnose the 
thymolipoma through the preoperative radiological study in myasthenic patients, but the 
postoperative improvement of myasthenia severity suggested that extended thymectomy 
might be the one of modalites for this group of patients. 
Keywords: thymolipoma, thymectomy
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ITP-040: EFFICACY OF PERIOPERATIVE HIGH DOSE PREDNISO-
LONE THERAPY IN MYASTHENIA GRAVIS PATIENTS WITH 
EXTENDED THYMECTOMY
Yoshito Yamada1, Shigetoshi Yoshida1, Hidemi Suzuki1, Tetsuzo Tagawa1, Takekazu 
Iwata1, Teruaki Mizobuchi1, Ichiro Yoshino2, Naoki Kawaguchi2  
1Department Of General Thoracic Surgery, Chiba University Graduate School Of 
Medicine, Chiba/JAPAN, 2Department Of Neurology, Chiba University Graduate School 
Of Medicine, Chiba/JAPAN
Background: Since 1978 we have offered perioperative high-dose prednisolone (PSL) 
therapy followed by extended thymectomy for myasthenia gravis (MG) patients in 
order to stabilize preoperative MG status, prevent from postoperative MG crisis, and 
achieve early remission of MG. The purpose of this study was to clarify the clinical 
benefits of perioperative administration of high-dose PSL combined with extended 
thymectomy in patients with MG. Methods: A retrospective review was conducted on 
patients with Myasthenia Gravis Foundation of America (MGFA) classification I to IIIb 
who had undergone extended thymectomy between 1992 and 2009. The perioperative 
high dose PSL therapy includes a preoperative alternative-day administration of PSL 
with escalating dose from 60mg to 100mg, a maintenance administration with PSL 
100mg/AD for perioperative one month, and postoperative tapering dose by 5mg /
month for more than 2 years. All patients were followed up for at least 3 years. This 
therapy was induced for those with patients’ consent and MGFA class IIa or more 
except advanced thymoma and good response to anti-ChE. Seventy patient were treated 
with perioperative high-dose PSL therapy (ph-PSL group), and sixty two patients did 
not received preoperative steroidal treatment (control group). These two groups were 
compared in clinical characteristics, incidences of postoperative MG crisis and other 
complications related to PSL, and follow-up outcome of MG status such as improved 
(imp), complete stable remission (CSR) and pharmacological remission (PR), according 
to the literature by Jaretzki et al. (Ann Thorac Surg, 2003 and Neurology 2003). Results: 
MG status of the first presentation was more serious in the ph-PSL group; MGFA 
IIB or above were 42 (60.0%) in ph-PSL group, and 7 (11.3%) in the control (p<0.01). 
Preoperative FEV1.0% was higher in the ph-PSL group than that in the control group 
(85.0±1.5% and 81.5±0.9%, respectively, p=0.04). There were no significant differences 
in other clinical features such as age, sex, preoperative FVC, anti-acetylcholine receptor 
antibody, administration of anti-cholinesterase, and presence of thymoma. In the ph-
PSL group, MG statuses were well stabilized before thymectomy. Consequently, MGFA 
classes in most of the cases were significantly downgraded (p<0.01), and administrations 
of anti-cholinesterase in the ph-PSL group could be withdrawn more than the control 
group (p<0.01). The ph-PSL group had significantly less incidence of postoperative 
MG crisis than the control (2.9% vs. 12.2%, p=0.04) while other complications such as 
infection, wound dehiscence, diabetes mellitus, hyperlipidemia and osteoporosis were 
observed similarly among both groups. From life table analysis, “imp” at 3/ 5 years 
were 92/ 96% in the ph-PSL group whereas those were 57/76% in the control (p<0.01). 
“CSR+PR” at 3/5/10 years were 23/42/72% in the ph-PSL group whereas those were 
10/20/44% in the control (p<0.01). Conclusion: The perioperative high-dose PSL therapy 
is a promising strategy for the management of MG patients in terms of the incidence of 
postoperative MG crisis, postoperative MG status and safety.
Keywords: myasthenia gravis, thymectomy, myasthenia gravis crisis, prednisolone
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ITP-041: PREOPERATIVE PLASMAPHERESIS OR IMMUNOGLOB-
ULIN ADMINISTRATION FOR THYMECTOMY IN MYASTHENIA 
GRAVIS. IS IT NECESSARY?
Apichat Tantraworasin, Sophon Siwachat, Somcharean Saeteang  
General Thoracic Unit, Department Of Surgery, Chiang Mai University, Chiang Mai/
THAILAND
Background: Plasmapheresis or intravenous immunoglobulin(IVIG) is used for 
treatment in myasthenic crisis patients. However, role of plasmapheresis and IVIG 
administration before surgery remains controversial, especially both in patients who 
have history of myasthenic crisis and in patients underwent elective surgery. In my 
country, patients must pay the cost of these treatments by themselves, therefore some 
of them can’t accept this cost. We performed elective thymectomy both in patients who 
received preoperative plasmapheresis or IVIG and in patients who did not. The aim of 
this study is to determine peri-operative and post-operative outcomes of thymectomy 
in myasthenic patients comparing between using and no using pre-operative 
plasmaphreresis or IVIG administration. Methods: We conduct retrospective study 
chart review in Chiang Mai University Hospital. Between January 2006 to December 
2011, thymectomy were performed in 86 myasthenic patients . Patients were divided 
into two group, one was preoperative plasmapheresis or IVIG group (PG) and another 
one was no preoperative plasmapheresis or IVIG group (NPG). Primary outcome was 
post-operative extubation, second outcome included post-operative complication, 28 
days mortality and length of hospital stay. Results: Eighty-six patients were enrolled in 
this study ,included 25 males and 61 females. Most of patients were classified in stage 
IIB(Osserman classification).The number of patients who have history of myasthenic 
crisis at any time or within 1 month and plasmapheresis or IVIG administration before 
surgery in PG were more than those in NPG significantly. Muscle power and forced 
expiratory vital capacity in NPG was higher than that in PG. Post –operative extubation 
was 87.9 percent in PG and was 94.3 percent in NPG (p = 0.421). Propensity score was 
used to adjust covariates or confounders between both groups. Immediate extubation 
after surgery, Post-operative complications, 28 days mortality and length of hospital 
stay were not statistically significant difference between both groups (table 1) Table 1: 
Post-operative outcomes of no plasmapheresis or immunoglobulin group compared with 
plasmapheresis or immunoglobulin group adjusted by propensity score. 
Variables Risk ratio 95%CI p-value 
Immediate extubation after surgery 1.07 0.92-1.25 0.349 
Post-operative complications 0.62 0.21-1.86 0.396 
28 days mortality 0.62 0.04-10.0 0.738 
Length of hospital stay* -0.93 -2.61-0.74 0.271 
 
*mean difference  Conclusion: The result of this study show no statistically significant 
difference between both groups in terms of primary post-operative extubation, post-
operative complication, length of hospital stay and 28 days mortality, therefore we can 
conclude that pre-operative plasmaphreresis or IVIG administration is not necessary for 
selective thymectomy in myasthetic patients.
Keywords: plasmapheresis, thymectomy, myasthenia gravis
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ITP-042: 81 MONTHS AFTER THYMECTOMY FOR B2-THYMOMA 
IN A 13-YEARS OLD BOY – A CASE REPORT
Marc Swierzy, Mahmoud Ismail, Jens C. Rückert  
Department For Surgery, Charité Medical School And University Hospital, Berlin/
GERMANY
Background: The prevalence of myasthenia gravis in children is 1-1.5 per 100 000 
population and 10 times less than in adults. In 10-15% there is an association with 
thymoma. Methods: We present the case of a 13-years old boy who was referred for 
surgical treatment of myasthenia gravis (MGFA IV according Myasthenia Gravis 
Foundation of America) and secondly for a strong suspicion of thymoma. Results: 
Since August 2005 the Patient suffered from weakness of voluntary muscles in legs and 
arms and later difficulty with swallowing, furthermore slurred speech. The patient had 
been already treated with 280 mg Mestinon. Thymectomy was performed minimally-
invasively with the daVinci-robotic-system. An extended resection including the left 
phrenic nerve and partial left upper lung resection was necessary due to adherence of 
the tumor. The histological finding showed a WHO B2, Masaoka stage 2 Thymoma. A 
subsequently radiation with 59.4 Gy was required. Eighty-one months after thymectomy 
the patient is in a good shape. Actually he is treated with 60 mg Mestinon and has only 
occasionally mild mimic symptoms resulting in MM-2 (minimal manifestations-2) 
according to MGFA postintervention-status. There still has been no recurrence detected. 
Conclusion: For patients younger than 18 years of age with acquired Ach-R-Ab positive 
MG with progressive symptoms thymectomy should be indicated without time-delay. In 
cases of suspicion of thymoma current treatment guidelines comprise complete surgical 
resection of thymoma and thymic gland. The adequate operation technique of choice 
is thoracoscopic thymectomy. The most promising approach might be robotic-assisted 
thymectomy.
Keywords: thymoma, myasthenia gravis, robotic-assisted thymectomy, children
ITMIG POSTER SESSION - November 25, 2012 09:00-18:00 and November 26, 2012 
08:30-12:00
ITP-043: A CASE REPORT OF MIDDLE MEDIASTINAL ATYPICAL 
CARCINOID TUMOR, RESPOND TO OCTREOTIDE LAR AND 
RADIATION THERAPY.
Kotaro Miyake1, Yasushi Shintani2, Kenichi Nishie3, Iwao Goma3, Koichi Onaru3, Isao 
Tachibana1, Atsushi Kumanogoh1, Meinoshin Okumura2, Yoshiyuki Osamura4  
1Respiratory Medecine, Allergy And Rheumatic Disease, Osaka University Graduate 
School Of Medicine, Osaka/JAPAN, 2Department Of General Thoracic Surgery, Osaka 
University Graduate School Of Medicine, Osaka/JAPAN, 3Respiratory Medicine, Sakai 
City Hospital, Sakai/JAPAN, 4Center For Diagnostic Pathology, International University 
Of Health And Welfare, Tokyo/JAPAN
Background: A 44-year-old female came to our hospital with abnormal chest X-ray 
found at routine health check in December 2009. 18-fluoro-2-deoxy-D-glucose positron 
emission tomography and computed tomography (FDG-PET/CT) detected a middle 
mediastinal tumor (SUVmax: 12.0) without other sites of abnormal accumulation. The 
cytology from transbronchial needle aspiration (TBNA) was of little diagnostic value, 
but the result of CT guided percutaneous needle biopsy revealed atypical carcinoid 
tumor. Ki-67 index was 10%, then the tumor was classified to Neuroendocrine tumor G2 
according to 2010 WHO classification. Incomplete membranous staining of somatostatin 
receptor type 2A was observed. There was no symptoms suggesting carcinoid syndrome 
such as diarrhea or flushing. 24-hour urinary excretion of 5-HIAA was 6.8mg, not 
elevated. FDG-PET and enhanced CT detected no metastasis. Surgical therapy was too 
risky or technically impossible because of direct invasion into the cardiac sac. Radiation 
therapy with total doses of 54Gy and octreotide LAR was initiated. The tumor responded 
partially, and then the tumor size was stable for 30 months until now. Carcinoid tumor 
originated from middle mediastinum is rare. Furthermore, carcinoid tumor is difficult 
to manage with nonoperative therapy. Herein we provide discussion about diagnosis and 
treatment for carcinoid tumor.
 
Methods: not applicable Results: not applicable Conclusion: not applicable
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ITP-044: RECURRENCE OF NEUROENDOCRINE TUMORS IN THE 
THYMUS 24 YEARS AFTER TOTAL EXCISION: A CASE REPORT
Miyako Kojo1, Masahumi Yamaguchi1, Eiko Inamasu1, Ryou Toyozawa1, Fumihiko 
Hirai2, Goji Toyokawa1, Yoshimasa Shiraishi2, Yosuke Morodomi1, Tomoyoshi 
Takenaka2, Takashi Seto1, Mitsuhiro Takenoyama1, Yukito Ichinose1  
1Thoracic Oncology, Kyushu Cancer Center, Fukuoka/JAPAN, 2Department Of Thoracic 
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Oncology, National Kyushu Cancer Center, Fukuoka/JAPAN
Background: A male in his seventies presented with chest pain on March 2012. He 
had had undergone an operation for an anterior mediastinal tumor 24 years earlier, 
and the pathological diagnosis had been thymoma. He underwent a medical checkup 
every 6 months for the next twenty years. Computed axial tomography scan revealed 
a mediastinal mass adjacent to the left lung, pericardium and sternum. There was no 
apparent invasion to the adjacent structures. The patient underwent surgical resection 
with a diagnosis of recurrent thymoma. Posterio-lateral mini-thoracotomy was made 
under video-assisted thoracoscopy. There were severe adhesions around the tumor, and 
the tumor seemed to invade to the left lung, pericardium, but not the chest wall. The 
tumor was extirpated in combination with partial resection of left lung and pericardium. 
The pathological diagnosis of the tumor was a well differentiated neuroendocrine tumor 
of the thymus. The specimen excised 24 years earlier was reexamined by a pathologist. 
The pathological diagnosis of the resected mediastinal tumor was a well differentiated 
neuroendocrine tumor. The revised pathological diagnosis of the previously resected 
thymoma was also re-confirmed to be a well differentiated neuroendocrine tumor. 
Primary neuroendocrine carcinomas of the thymus are rare among anterior mediastinal 
tumors. In the literature, the overall survival rate at 5 years is 82% for resected patients. 
We herein report a case of neuroendocrine carcinoma and described the pathological 
and clinical features.  Methods: not applicable Results: not applicable Conclusion: not 
applicable
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ITP-045: A CASE OF RECCURENT THYMOMA WITH PURE RED 
CELL APLASIA SUCCESSFULLY TREATED BY IMMUNOSUPPRES-
SIVE THERAPY
Tomonori Murayama, Yukihiro Yoshida  
Surgery, Asahi General Hospital, Asahi City/JAPAN
Background: Pure red cell aplasia (PRCA) is known to combine with thymoma. But only 
few cases are reported to combine with the relapse of thymoma. Methods: A 64-year-old 
woman who underwent partial resection of thymus for microinvasive thymoma, type 
B1 by WHO classification 14 years ago, suffered cough and fever 10 years later from 
the first operation. She admitted to our department and CT scan revealed that 4.4cm 
tumor located at her right anterior mediastinum, she was diagnosed as recurrence of 
thymoma. Three consecutive days of methylprednisolone pulse therapy showed partial 
remission, and extended thymectomy concomitant resection of chest wall and left 
innominate vein, reconstraction using ringed polytetrafluoroethylene (ePTFE) graft 
was performed. Pathological diagnosis was thymoma, type B1. Three years after the 
second operation, anemia was pointed out at the local clinic, and she was referred to our 
hospital. Her hemoglobin level was 4.6 g/dl. Bone marrow biopsy was performed and 
she was diagnosed as pure red cell aplasia, CT scan was performed at the same time, and 
pleural dissemination was pointed out. Cyclosporin A (170mg/day ) was started and 
her hematological test results improved. Five months after immunosuppressive therapy, 
CT scan showed partial response at her tumor size. Results: Our case showed the 
effectiveness for the immunosuppressive therapy. Conclusion: The therapeutic strategy 
for thymoma with PRCA is controversial. Some reports the success of the surgical 
management but some reports the need for the multimodality therapy.
Keywords: thymoma reccurence, thymoma with pure red cell aplasia
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ITP-046: DELAY CHRONIC MYELOID LEUKAEMIA IN A WOMAN 
WITH MYASTHENIA GRAVIS TREATED PREVIOUSLY BY THY-
MECTOMY 20 YEARS AGO.
Mehrdad Payandeh, Mehrnoush Aeinfar  
Kermanshah Universiy Of Medical Science, Taleghany, 6715847167/IRAN
Background: A rare case of CML have been described following treatment of myasthenia 
gravis associated with thymoma treated by thymectomy. We report a 45-yr-old woman 
with myasthenia gravis with thymoma who developed CML, recent 14 months after 20 
years of thymomectomy. Cytogenetic study showed translocation (9,22)(q34;q11) with 
80% showing double Ph chromosome. Reverse-transcriptase polymerase chain reaction 
(RT-PCR) of peripheral blood demonstrated the presence of p210(BCR/ABL) with b3a2 
transcripts. He was treated with imatinib and still remained in the chronic phase during 
the last 6 months of follow up. Her myasthenic symptoms remained stable. Methods: 
rare case presentation Results: The patient was put on imatinib 400 mg once a day. she 
was also started on steroids and pyridostigmine therapy and occasionally treatment 
with IVIG according to neurologist decision. Patient was under constant follow-up. Her 
leukocytosis reverted to normal. Re-evaluation at the end of 12 weeks showed regression 
of spleen with a complete hematological response. The patient also had complete 
resolution of ptosis and ophthalmoplegia . In view of resolution of ocular signs and 
symptoms with complete hematological and cytogenetics response with imatinib therapy 
a diagnosis of CML in chronic phase with paraneoplastic ocular myasthenia gravis was 
made. Paraneoplastic phenomenon in CML is exceptional.There was one case report 
of paraneoplastic digital necrosis with CML which occurred after 4 years of diagnosis 
of CML . There have been a few case reports of development of CML in a patient with 
existent myasthenia gravis (generalized form) following thymectomy or following long-
term 6-mercaptopurine treatment . In the latter reports, the diagnosis of generalized 
myasthenia gravis preceded the diagnosis of CML thereby suggesting secondary CML 
or therapy-related CML. Clinical profile and thorough evaluation of our patient revealed 
that she presented with CML which responded to imatinib therapy after many year of 
time that passed from diagnosis of myasthenia gravis. Conclusion: Myasthenia gravis 
has occasionally been associated with other tumors (SCLC, thyroid, and breast cancers, 
and Hodgkin lymphoma). Cml presentation with a mystenia gravis is a rare presentation 
for these disease This report(in CML and MG) so far in available literature.
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ITP-047: LYMPHOID HYPERPLASIA OF THE THYMUS MIMICK-
ING THYMIC MALIGNANCY: A CASE REPORT
Tomohito Saito1, Yukihito Saito2, Takahito Nakano2, Yohei Taniguchi2, Hiroyuki 
Kaneda2, Toshifumi Konobu2, Shaf Keshavjee3, Noriko Sakaida4, Naoko Uemura4  
1Latner Thoracic Surgery Research Laboratories, University Of Toronto, Toronto/
CANADA, 2Division Of Thoracic Surgery, Kansai Medical University Hirakata Hospital, 
Hirakata/JAPAN, 3Latner Thoracic Surgery Research Laboratories, University Of 
Toronto, Toronto/ON/CANADA, 4Department Of Surgical Pathology, Kansai Medical 
University, Moriguchi/JAPAN
Background: Lymphoid thymic hyperplasia is considered as a consequence of acquired 
inflammatory response which commonly accompanies autoimmunie diseases. Because 
it is a benign disease, noninvasive diagnosis such as medical imaging is important. Here 
we present an atypical case of lymphoid follicular thymic hyperplasia mimicking thymic 
malignancy. A 42-year old woman was admitted to our hospital because of enlargement 
of nodules in the thymus. She had been receiving medication for rheumatoid arthritis 
for 3 years and had received surgrery for breast cancer followed by adjuvant therapy with 
tamoxifen and LH-RH analogs 5 years prior to the admission. At the same time, biopsy 
for nodule of the thymus had been performed since it had been suspected as lymph node 
metastatsis. Although the initial pathological diagnosis was lymphoid hyperplasia of 
the thymus, the nodules in the thymus have increased in number and size. Maximum 
standardized uptake value (SUVmax) of the 18Fluorodeoxyglucose positron emission 
tomography (FDG-PET) was 7.9, which suggested thymic malignancy. Thymectomy 
was performed and the resected thymus showed diffuse enlargement and prominent 
medullary lymphoid follicles with germinal center and Hassall’’s corpuscles, which lead 
to diagnosis of lymphoid hyperplasia of the thymus. This is a case of lymphoid thymic 
hyperplasia mimicking malignancy with: 1) multiple nodules increasing in number 
and size over time, and 2) high SUVmax in FDG-PET. Further investigation should be 
necessary to establish the optimal noninvasive diagnosis for differentiating between 
benign and malignant thymic abnormalities. Methods: ‘not applicable’  Results: ‘not 
applicable’  Conclusion: ‘not applicable’ 
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ITP-048: A CASE OF MATURE CYSTIC TERATOMA PRESENTING 
A DRAMATICALLY RAPID GROWTH AND A LIFE THREATENING 
CLINICAL COURSE
Omachi Naoki, Tomoya Kawaguchi, Masaki Kanazu, Akihiro Tamiya, Kazuhiro Asami, 
Kyoichi Okishio, Shinji Atagi  
Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai/JAPAN
Background: We present a 23-years-old man with a mediastinal teratoma. Chest X ray 
showed only slight mass in the riht hilum at four months before admission. Tumor had 
rapidly grown within only four months and compressed right atrium markedly. Urgent 
surgery was performed, and ruptured benign mature cystic teratoma was diagnosed. 
The pathological examination confirmed perforation of mediastinal teraatoma into right 
plural cavity. The postoperative period was uneventful. Life threatening mature cystic 
teratoma in the anterior mediastinum, which has rapidly grown by rupture is extremely 
uncommon.  Methods: not applicable Results: not applicable Conclusion: not applicable 
Keywords: life threatening, teratoma
